Identification

Name
Cisplatin
Accession Number
DB00515  (APRD00359)
Type
Small Molecule
Groups
Approved
Description

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Structure
Thumb
Synonyms
  • CDDP
  • Cis-DDP
  • cis-diamminedichloroplatinum(II)
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CISplatinInjection, solution1 mg/mLIntravenousWG Critical Care, LLC2012-01-13Not applicableUs
CISplatinInjection, solution1 mg/mLIntravenousWG Critical Care, LLC2015-04-15Not applicableUs
CISplatinInjection, solution1 mg/mLIntravenousWG Critical Care, LLC2012-01-13Not applicableUs
Cisplatin Inj 0.5mg/mlLiquid.5 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311996-09-10Canada
Cisplatin Inj 1mg/mlLiquid1 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1986-12-311998-08-13Canada
Cisplatin InjectionSolution1.0 mgIntravenousTeva2013-08-29Not applicableCanada
Cisplatin InjectionSolution1 mgIntravenousOmega Laboratories LtdNot applicableNot applicableCanada
Cisplatin InjectionSolution1 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Cisplatin InjectionSolution1 mgIntravenousFresenius KabiNot applicableNot applicableCanada
Cisplatin Injection BPSolution1 mgIntravenousPfizer1997-05-09Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CisplatinInjection1 mg/mLIntravenousMylan Institutional2012-04-192018-02-08Us
CisplatinInjection, solution100 mg/100mLIntravenousTeva Parenteral Medicines, Inc.2000-06-01Not applicableUs
CisplatinInjection, solution100 mg/100mLIntravenousAlvogen, Inc.2017-09-25Not applicableUs
CisplatinInjection, solution1 mg/mLIntravenousAthenex Pharmaceutical Division, Llc.2017-06-12Not applicableUs
CisplatinInjection1 mg/mLIntravenousBlue Point Laboratories2016-08-02Not applicableUs
CisplatinInjection1 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-04-192018-04-07Us
CisplatinInjection, solution50 mg/50mLIntravenousAlvogen, Inc.2017-09-25Not applicableUs
CisplatinInjection, solution1 mg/mLIntravenousGland Pharma Limited2017-04-03Not applicableUs
CisplatinInjection, solution50 mg/50mLIntravenousTeva Parenteral Medicines, Inc.2000-06-01Not applicableUs
CisplatinInjection1 mg/mLIntravenousMylan Institutional2012-04-192018-02-08Us
International/Other Brands
Abiplatin / Cisplatyl / Platidiam / Platin (Cadila Healthcare) / Platinol-AQ
Categories
UNII
Q20Q21Q62J
CAS number
15663-27-1
Weight
Average: 298.035
Monoisotopic: 296.939928001
Chemical Formula
Cl2H4N2Pt
InChI Key
DQLATGHUWYMOKM-UHFFFAOYSA-L
InChI
InChI=1S/2ClH.2H2N.Pt/h2*1H;2*1H2;/q;;2*-1;+4/p-2
IUPAC Name
dichloroplatinumdiamine
SMILES
N[Pt](N)(Cl)Cl

Pharmacology

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Pharmacodynamics

Cisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.

Mechanism of action

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

TargetActionsOrganism
ADNA
cross-linking/alkylation
Human
UDNA-3-methyladenine glycosylaseNot AvailableHuman
UAlpha-2-macroglobulinNot AvailableHuman
USerotransferrinNot AvailableHuman
UCopper transport protein ATOX1Not AvailableHuman
Absorption

Following cisplatin doses of 20 to 120 mg/m^2, the concentrations of platinum are highest in liver, prostate, and kidney; somewhat lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum. Platinum is present in tissues for as long as 180 days after the last administration.

Volume of distribution

Volume of distribution at steady state = 11-12 L/m^2

Protein binding

Cisplatin does not undergo instantaneous and reversible binding to plasma protein that is characteristic of normal drug-protein binding. However, the platinum itself is capable of binding to plasma proteins, including albumin, transferrin, and gamma globulin. Three hours after a bolus injection and two hours after the end of a three-hour infusion, 90% of the plasma platinum is protein bound.

Metabolism
Not Available
Route of elimination

The parent compound, cisplatin, is excreted in the urine. Although small amounts of platinum are present in the bile and large intestine after administration of cisplatin, the fecal excretion of platinum appears to be insignificant.

Half life

Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2. Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.

Clearance
  • 15-16 L/h/m^2 [total body clearance, 7-hour infusion of 100 mg/m^2]
  • 62 mL/min/m^2 [renal clearance, 2-hour infusion of 100 mg/m^2]
  • 50 mL/min/m^2 [renal clearance, 6- to 7-hour infusion of 100 mg/m^2] The renal clearance of free (ultrafilterable) platinum also exceeds the glomerular filtration rate indicating that cisplatin or other platinum-containing molecules are actively secreted by the kidneys. The renal clearance of free platinum is nonlinear and variable and is dependent on dose, urine flow rate, and individual variability in the extent of active secretion and possible tubular reabsorption.
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Glutathione S-transferase Mu 1GSTM1Not Availablepresence of functional GSTM1ADR Directly StudiedPatients with this genotype have increased risk of ototoxicity with [durg: cisplatin].Details
Low-density lipoprotein receptor-related protein 2---(A;A) / (A;G)---ADR Directly StudiedPatients with this genotype have increased risk of ototoxicity with [durg: cisplatin].Details
Glutathione S-transferase P---(A;G) / (G;G)---ADR Directly StudiedPatients with this genotype have increased risk of ototoxicity with [durg: cisplatin].Details
DNA repair protein complementing XP-C cells---(C;C)---ADR Directly StudiedPatients with this genotype have increased risk of ototoxicity with [durg: cisplatin].Details

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Cisplatin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Cisplatin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Cisplatin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Cisplatin.Experimental, Illicit
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Cisplatin.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Cisplatin.Approved, Experimental, Investigational
AcenocoumarolCisplatin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe serum concentration of Cisplatin can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cisplatin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Cisplatin.Experimental
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Cisplatin.Approved
AgmatineThe serum concentration of Agmatine can be increased when it is combined with Cisplatin.Experimental, Investigational
AlaproclateAlaproclate may increase the antiplatelet activities of Cisplatin.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Cisplatin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Cisplatin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Cisplatin.Experimental, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Cisplatin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Cisplatin.Approved
AmikacinCisplatin may increase the nephrotoxic activities of Amikacin.Approved, Investigational, Vet Approved
AmiodaroneThe serum concentration of Cisplatin can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Cisplatin can be increased when it is combined with Amlodipine.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Cisplatin.Approved, Investigational, Withdrawn
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Cisplatin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Cisplatin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Cisplatin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Cisplatin.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Cisplatin.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Cisplatin is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Cisplatin.Approved, Investigational
ApalutamideThe serum concentration of Cisplatin can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Cisplatin.Investigational
ApramycinCisplatin may increase the nephrotoxic activities of Apramycin.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Cisplatin.Approved, Investigational
ArbekacinCisplatin may increase the nephrotoxic activities of Arbekacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Cisplatin.Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Cisplatin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cisplatin.Approved
AzosemideThe risk or severity of ototoxicity and nephrotoxicity can be increased when Azosemide is combined with Cisplatin.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Cisplatin is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Cisplatin is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BacitracinThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Cisplatin.Approved, Investigational
BazedoxifeneCisplatin may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cisplatin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Cisplatin is combined with Beclomethasone dipropionate.Approved, Investigational
BekanamycinCisplatin may increase the nephrotoxic activities of Bekanamycin.Experimental
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Cisplatin.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Cisplatin.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Cisplatin.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Cisplatin.Approved
BepridilThe serum concentration of Cisplatin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Cisplatin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Cisplatin.Approved, Investigational
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Cisplatin.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Cisplatin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Cisplatin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Cisplatin is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Cisplatin.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Cisplatin.Experimental
BumetanideThe risk or severity of ototoxicity and nephrotoxicity can be increased when Bumetanide is combined with Cisplatin.Approved
BupropionThe serum concentration of Cisplatin can be increased when it is combined with Bupropion.Approved
CabazitaxelCisplatin may increase the myelosuppressive activities of Cabazitaxel.Approved
CaffeineThe serum concentration of Cisplatin can be increased when it is combined with Caffeine.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Cisplatin.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Cisplatin.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Cisplatin can be increased when it is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Cisplatin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Cisplatin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Cisplatin.Approved, Investigational, Vet Approved
ChlorotrianiseneCisplatin may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenamineThe serum concentration of Cisplatin can be increased when it is combined with Chlorphenamine.Approved
ChlorthalidoneThe risk or severity of ototoxicity and nephrotoxicity can be increased when Chlorthalidone is combined with Cisplatin.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Cisplatin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Cisplatin.Approved, Investigational
CimetidineThe serum concentration of Cisplatin can be increased when it is combined with Cimetidine.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Cisplatin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Cisplatin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Cisplatin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Cisplatin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Cisplatin.Approved
ClorindioneCisplatin may increase the anticoagulant activities of Clorindione.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Cisplatin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClozapineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Clozapine.Approved
Conjugated estrogensCisplatin may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Cisplatin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Cisplatin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Cisplatin.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Cisplatin is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Cisplatin.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Cisplatin.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cisplatin.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Cisplatin.Experimental
DaidzeinCisplatin may increase the thrombogenic activities of Daidzein.Experimental
DapoxetineDapoxetine may increase the antiplatelet activities of Cisplatin.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Cisplatin.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cisplatin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cisplatin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Cisplatin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Cisplatin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Cisplatin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Cisplatin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Cisplatin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Cisplatin.Vet Approved
DexniguldipineThe serum concentration of Cisplatin can be increased when it is combined with Dexniguldipine.Experimental
DexverapamilThe serum concentration of Cisplatin can be increased when it is combined with Dexverapamil.Experimental
DibekacinCisplatin may increase the nephrotoxic activities of Dibekacin.Experimental
DiclofenacThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Diclofenac.Approved, Vet Approved
DicoumarolCisplatin may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolCisplatin may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolCisplatin may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Cisplatin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Cisplatin.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cisplatin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Cisplatin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Cisplatin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cisplatin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Cisplatin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cisplatin.Approved
DihydrostreptomycinCisplatin may increase the nephrotoxic activities of Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe serum concentration of Cisplatin can be increased when it is combined with Diltiazem.Approved, Investigational
DiphenadioneCisplatin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe serum concentration of Cisplatin can be increased when it is combined with Diphenhydramine.Approved, Investigational
DocetaxelCisplatin may increase the myelosuppressive activities of Docetaxel.Approved, Investigational
DoxazosinThe serum concentration of Cisplatin can be increased when it is combined with Doxazosin.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Cisplatin.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Cisplatin.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Cisplatin.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Cisplatin.Investigational
EltrombopagThe serum concentration of Cisplatin can be increased when it is combined with Eltrombopag.Approved
EmopamilThe serum concentration of Cisplatin can be increased when it is combined with Emopamil.Experimental
EpimestrolCisplatin may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Cisplatin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Cisplatin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Cisplatin.Approved
EquolCisplatin may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Cisplatin.Approved, Investigational
EstradiolCisplatin may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateCisplatin may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateCisplatin may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateCisplatin may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolCisplatin may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedCisplatin may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneCisplatin may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Cisplatin.Approved
Etacrynic acidThe risk or severity of ototoxicity and nephrotoxicity can be increased when Etacrynic acid is combined with Cisplatin.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Cisplatin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Cisplatin.Experimental
Ethinyl EstradiolCisplatin may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateCisplatin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Cisplatin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Cisplatin.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Cisplatin.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Cisplatin.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Cisplatin.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Cisplatin.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Cisplatin.Investigational
FamotidineThe serum concentration of Cisplatin can be increased when it is combined with Famotidine.Approved
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Cisplatin.Experimental
FelodipineThe serum concentration of Cisplatin can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Cisplatin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Cisplatin.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Cisplatin.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Cisplatin.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Cisplatin.Experimental
FingolimodCisplatin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Cisplatin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Cisplatin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Cisplatin.Approved, Investigational
FluindioneCisplatin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Cisplatin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Cisplatin.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Cisplatin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Cisplatin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Cisplatin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Cisplatin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Cisplatin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Cisplatin.Approved, Investigational
FluoxetineThe serum concentration of Cisplatin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Cisplatin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Cisplatin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Cisplatin.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Cisplatin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Cisplatin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Cisplatin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Cisplatin is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Cisplatin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Cisplatin.Approved, Investigational, Withdrawn
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Cisplatin.Approved, Investigational
FramycetinCisplatin may increase the nephrotoxic activities of Framycetin.Approved
FurosemideThe risk or severity of ototoxicity and nephrotoxicity can be increased when Furosemide is combined with Cisplatin.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Cisplatin is combined with G17DT.Investigational
GallopamilThe serum concentration of Cisplatin can be increased when it is combined with Gallopamil.Investigational
GeneticinCisplatin may increase the nephrotoxic activities of Geneticin.Experimental
GenisteinCisplatin may increase the thrombogenic activities of Genistein.Investigational
GentamicinCisplatin may increase the nephrotoxic activities of Gentamicin.Approved, Vet Approved
GENTAMICIN C1ACisplatin may increase the nephrotoxic activities of GENTAMICIN C1A.Experimental
GI-5005The risk or severity of adverse effects can be increased when Cisplatin is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Cisplatin.Experimental
GlycerinThe serum concentration of Cisplatin can be increased when it is combined with Glycerin.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Cisplatin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Cisplatin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Cisplatin.Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Cisplatin is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolCisplatin may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Cisplatin.Investigational
HistamineThe serum concentration of Cisplatin can be increased when it is combined with Histamine.Approved, Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Human rabies virus immune globulin.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Cisplatin is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Cisplatin is combined with Hydrocortisone acetate.Approved, Vet Approved
HydroflumethiazideThe risk or severity of ototoxicity and nephrotoxicity can be increased when Hydroflumethiazide is combined with Cisplatin.Approved, Investigational
Hygromycin BCisplatin may increase the nephrotoxic activities of Hygromycin B.Vet Approved
IbuprofenThe serum concentration of Cisplatin can be increased when it is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Cisplatin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Cisplatin.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Cisplatin.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Cisplatin.Investigational, Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Cisplatin.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Cisplatin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Cisplatin.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Cisplatin is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Cisplatin is combined with INGN 225.Investigational
IsavuconazoleThe serum concentration of Cisplatin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsepamicinCisplatin may increase the nephrotoxic activities of Isepamicin.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Cisplatin.Withdrawn
IsradipineThe serum concentration of Cisplatin can be increased when it is combined with Isradipine.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Cisplatin.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Cisplatin is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KanamycinCisplatin may increase the nephrotoxic activities of Kanamycin.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Cisplatin.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Cisplatin.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Cisplatin.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Cisplatin.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Cisplatin.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Cisplatin is combined with Leflunomide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Cisplatin.Approved, Investigational
LidocaineThe serum concentration of Cisplatin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LipegfilgrastimCisplatin may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
Lipoic AcidThe therapeutic efficacy of Cisplatin can be decreased when used in combination with Lipoic Acid.Approved, Investigational, Nutraceutical
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cisplatin.Investigational
LomerizineThe serum concentration of Cisplatin can be increased when it is combined with Lomerizine.Experimental
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Cisplatin.Experimental
LoperamideThe serum concentration of Cisplatin can be increased when it is combined with Loperamide.Approved
LoratadineThe serum concentration of Cisplatin can be increased when it is combined with Loratadine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Cisplatin.Approved, Investigational
LosartanThe serum concentration of Cisplatin can be increased when it is combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Cisplatin.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Cisplatin.Approved, Investigational
LumacaftorThe serum concentration of Cisplatin can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Cisplatin.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cisplatin.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Cisplatin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Cisplatin.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cisplatin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Cisplatin.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Cisplatin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Cisplatin.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Cisplatin.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Cisplatin.Approved
MestranolCisplatin may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Cisplatin.Approved, Investigational, Withdrawn
MetforminThe serum concentration of Cisplatin can be increased when it is combined with Metformin.Approved
MethallenestrilCisplatin may increase the thrombogenic activities of Methallenestril.Experimental
MethyclothiazideThe risk or severity of ototoxicity and nephrotoxicity can be increased when Methyclothiazide is combined with Cisplatin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Cisplatin is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Cisplatin.Experimental
MetoprololThe serum concentration of Cisplatin can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Cisplatin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Cisplatin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinCisplatin may increase the nephrotoxic activities of Micronomicin.Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Cisplatin.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cisplatin.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Cisplatin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Cisplatin.Approved, Vet Approved
MoxestrolCisplatin may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Cisplatin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cisplatin.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Cisplatin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cisplatin.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Cisplatin.Approved
NaproxenThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Naproxen.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Cisplatin.Investigational
NeamineCisplatin may increase the nephrotoxic activities of Neamine.Experimental
NefazodoneNefazodone may increase the antiplatelet activities of Cisplatin.Approved, Withdrawn
NeomycinThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Cisplatin.Approved, Investigational
NetilmicinCisplatin may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
NicardipineThe serum concentration of Cisplatin can be increased when it is combined with Nicardipine.Approved, Investigational
NicotineThe serum concentration of Cisplatin can be increased when it is combined with Nicotine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Cisplatin.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Cisplatin.Approved
NiguldipineThe serum concentration of Cisplatin can be increased when it is combined with Niguldipine.Experimental
NimesulideThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Cisplatin can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Cisplatin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Cisplatin can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Cisplatin.Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Cisplatin.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Cisplatin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Cisplatin.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cisplatin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Cisplatin.Approved
OmeprazoleThe serum concentration of Cisplatin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Cisplatin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Cisplatin.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Cisplatin.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cisplatin.Approved, Withdrawn
PaclitaxelCisplatin may increase the myelosuppressive activities of Paclitaxel.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Cisplatin.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Cisplatin.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Cisplatin.Approved
ParomomycinCisplatin may increase the nephrotoxic activities of Paromomycin.Approved, Investigational
ParoxetineThe serum concentration of Cisplatin can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Cisplatin.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Cisplatin.Experimental
PhenindioneCisplatin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCisplatin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Cisplatin.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Cisplatin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cisplatin.Approved, Investigational
PiretanideThe risk or severity of ototoxicity and nephrotoxicity can be increased when Piretanide is combined with Cisplatin.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Cisplatin.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cisplatin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Cisplatin.Experimental
PitolisantThe serum concentration of Cisplatin can be decreased when it is combined with Pitolisant.Approved, Investigational
PlazomicinCisplatin may increase the nephrotoxic activities of Plazomicin.Approved, Investigational
Polyestradiol phosphateCisplatin may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PramipexoleThe serum concentration of Pramipexole can be increased when it is combined with Cisplatin.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Cisplatin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Cisplatin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Cisplatin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Cisplatin.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Cisplatin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Cisplatin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Cisplatin.Approved, Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Cisplatin.Experimental
PromestrieneCisplatin may increase the thrombogenic activities of Promestriene.Investigational
PromethazineThe serum concentration of Cisplatin can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Cisplatin.Approved, Investigational
PropafenoneThe serum concentration of Cisplatin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Cisplatin can be increased when it is combined with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Cisplatin.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Cisplatin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Cisplatin.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Cisplatin.Investigational
PuromycinCisplatin may increase the nephrotoxic activities of Puromycin.Experimental
QuinestrolCisplatin may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe risk or severity of ototoxicity and nephrotoxicity can be increased when Quinethazone is combined with Cisplatin.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Cisplatin is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cisplatin.Approved, Investigational
RanitidineThe serum concentration of Cisplatin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Cisplatin can be increased when it is combined with Ranolazine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cisplatin.Approved, Experimental, Investigational
RibostamycinCisplatin may increase the nephrotoxic activities of Ribostamycin.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Cisplatin.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Cisplatin is combined with Rindopepimut.Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Cisplatin.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Cisplatin.Approved
RolapitantThe serum concentration of Cisplatin can be increased when it is combined with Rolapitant.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Rubella virus vaccine.Approved, Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Cisplatin.Approved
Salicylic acidThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Salicylic acid.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Cisplatin is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of adverse effects can be increased when Cisplatin is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Cisplatin.Approved
SecoisolariciresinolCisplatin may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Cisplatin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Cisplatin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Cisplatin.Investigational
SertralineSertraline may increase the antiplatelet activities of Cisplatin.Approved
SisomicinCisplatin may increase the nephrotoxic activities of Sisomicin.Investigational
SRP 299The risk or severity of adverse effects can be increased when Cisplatin is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Cisplatin.Investigational
StreptomycinCisplatin may increase the nephrotoxic activities of Streptomycin.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Cisplatin.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Cisplatin.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Cisplatin.Experimental
Synthetic Conjugated Estrogens, ACisplatin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BCisplatin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusTacrolimus may increase the immunosuppressive activities of Cisplatin.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Cisplatin.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Cisplatin is combined with Tecemotide.Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Cisplatin.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Cisplatin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Cisplatin.Vet Approved
TeriflunomideThe serum concentration of Cisplatin can be increased when it is combined with Teriflunomide.Approved
TetrandrineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Tetrandrine.Experimental
TG4010The risk or severity of adverse effects can be increased when Cisplatin is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Cisplatin.Approved
TiboloneCisplatin may increase the thrombogenic activities of Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Cisplatin.Investigational
TioclomarolCisplatin may increase the anticoagulant activities of Tioclomarol.Experimental
TipiracilThe serum concentration of Tipiracil can be increased when it is combined with Cisplatin.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Cisplatin.Approved, Withdrawn
TobramycinCisplatin may increase the nephrotoxic activities of Tobramycin.Approved, Investigational
TofacitinibCisplatin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Cisplatin.Approved
TopotecanThe risk or severity of adverse effects can be increased when Cisplatin is combined with Topotecan.Approved, Investigational
TorasemideThe risk or severity of ototoxicity and nephrotoxicity can be increased when Torasemide is combined with Cisplatin.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cisplatin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Cisplatin.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Cisplatin.Experimental
TrichlormethiazideThe risk or severity of ototoxicity and nephrotoxicity can be increased when Trichlormethiazide is combined with Cisplatin.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Cisplatin.Investigational
Trolamine salicylateThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Trolamine salicylate.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Typhoid Vaccine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Cisplatin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Cisplatin.Approved, Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Cisplatin is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VemurafenibThe serum concentration of Cisplatin can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Cisplatin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Cisplatin can be increased when it is combined with Verapamil.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine.Approved, Investigational
WarfarinCisplatin may increase the anticoagulant activities of Warfarin.Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Cisplatin is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cisplatin.Approved, Investigational
ZeranolCisplatin may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Cisplatin.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Cisplatin.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cisplatin.Withdrawn
Food Interactions
  • Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use.

References

Synthesis Reference

Murray A. Kaplan, Alphonse P. Granatek, "Process for the preparation of microcrystalline cisplatin." U.S. Patent US4322391, issued March 30, 1982.

US4322391
General References
Not Available
External Links
Human Metabolome Database
HMDB0014656
KEGG Drug
D00275
KEGG Compound
C06911
PubChem Compound
2767
PubChem Substance
46504561
ChemSpider
2665
BindingDB
50028111
ChEBI
27899
ChEMBL
CHEMBL2068237
Therapeutic Targets Database
DAP000215
PharmGKB
PA449014
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cisplatin
ATC Codes
L01XA01 — Cisplatin
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (413 KB)
MSDS
Download (76.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedDiagnosticHead and Neck Carcinoma1
0CompletedPreventionGastro-esophageal Junction Cancer / Malignant Neoplasm of Stomach1
0CompletedTreatmentHead and Neck Carcinoma1
0CompletedTreatmentHead and Neck Carcinoma / Pharynx Cancer1
0Not Yet RecruitingTreatmentProstate Cancer1
0RecruitingTreatmentAdenocarcinoma of the Pancreas1
0RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
0TerminatedTreatmentHead and Neck Carcinoma1
1Active Not RecruitingTreatmentAdenocarcinoma of Lung Stage IV1
1Active Not RecruitingTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Positive Para-Aortic Lymph Node / Positive Pelvic Lymph Node / Stage IB Cervical Cancer / Stage IB2 Cervical Cancer / Stage IB2 Cervical Cancer AJCC v6 and v7 / Stage II Cervical Cancer / Stage II Cervical Cancer AJCC v7 / Stage IIA Cervical Cancer / Stage IIA Cervical Cancer AJCC v7 / Stage IIB Cervical Cancer / Stage IIB Cervical Cancer AJCC v6 and v7 / Stage IIIB Cervical Cancer / Stage IIIB Cervical Cancer AJCC v6 and v7 / Stage IVA Cervical Cancer / Stage IVA Cervical Cancer AJCC v6 and v71
1Active Not RecruitingTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer1
1Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Non-Small Cell Lung Cancer Recurrent / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1Active Not RecruitingTreatmentAdvanced Solid Tumors2
1Active Not RecruitingTreatmentAmpullary Cancer / Biliary Tract Cancer / Cholangiocarcinomas / Gallbladder Cancer1
1Active Not RecruitingTreatmentBile Duct Carcinoma / Carcinoma of Gallbladder / Carcinoma of Intrahepatic and Extra-hepatic Biliary System / Cholangiocarcinomas1
1Active Not RecruitingTreatmentBiliary Tract Carcinoma / Cancer, Advanced / Cholangiocarcinomas / Gall Bladder Carcinoma / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL) / Tumors, Solid1
1Active Not RecruitingTreatmentBladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureteral Cancer / Urethral Cancer1
1Active Not RecruitingTreatmentCancer of Head and Neck1
1Active Not RecruitingTreatmentCancer of Nasopharynx / Carcinoma of Larynx / Carcinoma, Squamous Cell of Head and Neck / Early Invasive Cervical Squamous Cell Carcinoma / HPV Positive Oropharyngeal Squamous Cell Carcinoma / Hypopharyngeal Cancer1
1Active Not RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1Active Not RecruitingTreatmentFallopian Tube Carcinosarcoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Neoplasm / Fallopian Tube Transitional Cell Carcinoma / Ovarian Brenner Tumor / Ovarian Carcinosarcoma / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Tumor / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Tumor / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Fallopian Tube Cancer AJCC v6 and v7 / Stage IIA Ovarian Cancer / Stage IIA Ovarian Cancer AJCC V6 and v7 / Stage IIB Fallopian Tube Cancer / Stage IIB Fallopian Tube Cancer AJCC v6 and v7 / Stage IIB Ovarian Cancer / Stage IIB Ovarian Cancer AJCC v6 and v7 / Stage IIC Fallopian Tube Cancer / Stage IIC Fallopian Tube Cancer AJCC v6 and v7 / Stage IIC Ovarian Cancer / Stage IIC Ovarian Cancer AJCC v6 and v7 / Stage IIIA Fallopian Tube Cancer / Stage IIIA Fallopian Tube Cancer AJCC v7 / Stage IIIA Ovarian Cancer / Stage IIIA Ovarian Cancer AJCC v6 and v7 / Stage IIIA Primary Peritoneal Cancer / Stage IIIA Primary Peritoneal Cancer AJCC v7 / Stage IIIB Fallopian Tube Cancer / Stage IIIB Fallopian Tube Cancer AJCC v7 / Stage IIIB Ovarian Cancer / Stage IIIB Ovarian Cancer AJCC v6 and v7 / Stage IIIB Primary Peritoneal Cancer / Stage IIIB Primary Peritoneal Cancer AJCC v7 / Stage IIIC Fallopian Tube Cancer / Stage IIIC Fallopian Tube Cancer AJCC v7 / Stage IIIC Ovarian Cancer / Stage IIIC Ovarian Cancer AJCC v6 and v7 / Stage IIIC Primary Peritoneal Cancer / Stage IIIC Primary Peritoneal Cancer AJCC v7 / Stage IV Fallopian Tube Cancer / Stage IV Fallopian Tube Cancer AJCC v6 and v7 / Stage IV Ovarian Cancer / Stage IV Ovarian Cancer AJCC v6 and v7 / Stage IV Primary Peritoneal Cancer / Stage IV Primary Peritoneal Cancer AJCC v7 / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
1Active Not RecruitingTreatmentHead and Neck Carcinoma1
1Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Stage III Laryngeal Squamous Cell Carcinoma / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma1
1Active Not RecruitingTreatmentHuman Papillomavirus Infections / Stage III Hypopharyngeal Squamous Cell Carcinoma / Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage III Laryngeal Squamous Cell Carcinoma / Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7 / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Hypopharyngeal Squamous Cell Carcinoma / Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v71
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
1Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1Active Not RecruitingTreatmentLung Cancers2
1Active Not RecruitingTreatmentLymphoma, Hodgkins / Refractory / Relapses1
1Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Peripheral T-Cell Lymphoma (PTCL)1
1Active Not RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
1Active Not RecruitingTreatmentMetastatic Malignant Neoplasm in the Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Adult Soft Tissue Sarcoma / Stage IV Non-Small Cell Lung Cancer1
1Active Not RecruitingTreatmentOncology, Medical1
1Active Not RecruitingTreatmentTumors, Solid1
1Active Not RecruitingTreatmentUrothelial Carcinoma of the Urinary Bladder1
1CompletedNot AvailableCancer of the Ovary / Head and Neck Carcinoma / Lung Cancers / Neurotoxicity1
1CompletedSupportive CareDrug/Agent Toxicity by Tissue/Organ / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAbdominal wall neoplasm / Adenocarcinomas / Adrenocortical Carcinoma / Desmoplastic Small Round Cell Tumor (DSRCT) / Neoplasms, Gastrointestinal / Neoplasms, Ovarian / Neuroblastomas / Retroperitoneal Neoplasms / Rhabdomyosarcomas / Sarcomas / Wilms' tumor1
1CompletedTreatmentAbdominal wall neoplasm / Carcinoma NOS1
1CompletedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Adenocarcinoma of the Gallbladder / Adenocarcinoma of the Pancreas / Adult Primary Cholangiocellular Carcinoma / Advanced Adult Primary Liver Cancer / Ampulla of Vater Adenocarcinoma / Cholangiocarcinoma of the Gallbladder / Duct Cell Adenocarcinoma of the Pancreas / Gallbladder Adenocarcinoma / Localized Unresectable Adult Primary Liver Cancer / Pancreatic Adenocarcinoma Metastatic / Periampullary Adenocarcinoma / Recurrent Adult Primary Liver Cancer / Recurrent Gallbladder Cancer / Recurrent Pancreatic Cancer / Stage II Gallbladder Cancer / Stage III Ampulla of Vater Cancer / Stage III Intrahepatic Cholangiocarcinoma / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Hilar Cholangiocarcinoma / Stage IIIB Gallbladder Cancer / Stage IIIB Hilar Cholangiocarcinoma / Stage IV Ampulla of Vater Cancer / Stage IV Pancreatic Cancer / Stage IVA Gallbladder Cancer / Stage IVA Hilar Cholangiocarcinoma / Stage IVA Intrahepatic Cholangiocarcinoma / Stage IVA Pancreatic Cancer / Stage IVB Gallbladder Cancer / Stage IVB Hilar Cholangiocarcinoma / Stage IVB Intrahepatic Cholangiocarcinoma / Stage IVB Pancreatic Cancer1
1CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Small Cell Carcinoma / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer2
1CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Recurrent Cervical Carcinoma / Stage IVB Cervical Cancer1
1CompletedTreatmentAdenocarcinoma of the Cervix / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer1
1CompletedTreatmentAdenocarcinoma of the Ovaries / Fallopian Tube Adenocarcinoma / Primary Peritoneal Carcinoma1
1CompletedTreatmentAdvanced Gastric Cancer / Stomach Neoplasms1
1CompletedTreatmentAdvanced Solid Tumors3
1CompletedTreatmentBiliary Tract Cancer1
1CompletedTreatmentBiliary Tract Neoplasms / Cholangiocarcinomas / Gallbladder Neoplasms1
1CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter2
1CompletedTreatmentBrenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
1CompletedTreatmentCancer of Parotid / Head and Neck Carcinoma / Malignant Neoplasm of Thyroid / Melanoma / Parotid Gland Cancer / Stage IV Head and Neck Cancer / Thyroid neoplasms malignant1
1CompletedTreatmentCancer of the Ovary1
1CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Peritoneal Cavity Cancer2
1CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCancer of the Ovary / Head and Neck Carcinoma / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Advanced2
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCancer, Breast / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Mesothelioma / Prostate Cancer / Sarcomas1
1CompletedTreatmentCancer, Breast / Melanoma (Skin) / Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancers5
1CompletedTreatmentCancers / Neoplasms1
1CompletedTreatmentCancers / Tumors, Solid1
1CompletedTreatmentCarcinoma Neuroendocrine / Malignant Epithelial Neoplasms / Small Cell Lung Carcinoma1
1CompletedTreatmentCervical Cancers5
1CompletedTreatmentCervix Cancer1
1CompletedTreatmentChemotherapeutic Agent Toxicity / Endometrial Adenocarcinomas / Fallopian Tube Carcinoma / Gastrointestinal Complications / Malignant Ovarian Mixed Epithelial Tumor / Neurotoxicity Syndrome / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Primary Peritoneal Carcinoma / Stage II Ovarian Cancer / Stage III Ovarian Cancer / Stage IV Ovarian Cancer / Undifferentiated Ovarian Carcinoma1
1CompletedTreatmentCholangiocarcinoma of the Gallbladder / Localized Gallbladder Cancer / Unresectable Gallbladder Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers / Lung Cancers1
1CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer1
1CompletedTreatmentEndometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Squamous Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1CompletedTreatmentEndometrial Cancers1
1CompletedTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer1
1CompletedTreatmentEsophageal Cancers3
1CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
1CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentEsophagus Disorders / Squamous Carcinoma of Esophagus1
1CompletedTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Hereditary Breast/Ovarian Cancer - BRCA1 / Hereditary Breast/Ovarian Cancer - BRCA2 / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
1CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Unspecified Adult Solid Tumor, Protocol Specific2
1CompletedTreatmentHER-2 Gene Amplification1
1CompletedTreatmentHNSCC1
1CompletedTreatmentHead & Neck Cancer1
1CompletedTreatmentHead and Neck Carcinoma5
1CompletedTreatmentHead and Neck Carcinoma / Laryngeal Cancer / Oral Cancers / Pharyngeal Cancer / Squamous Carcinoma1
1CompletedTreatmentHead and Neck Carcinoma / Salivary Gland Tumors1
1CompletedTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma (SCC)1
1CompletedTreatmentHepatic Complications1
1CompletedTreatmentHepatocellular,Carcinoma / Liver Cancer / Localized Unresectable Liver Cancer1
1CompletedTreatmentImpaired Hepatic Function1
1CompletedTreatmentImpaired Renal Function1
1CompletedTreatmentInoperable Locally Advanced Non Small Cell Lung Cancer1
1CompletedTreatmentLocally Advanced Nasopharyngeal Carcinoma1
1CompletedTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV / Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Ovarian Epithelial Cancer1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Tumors, Solid1
1CompletedTreatmentLung Cancers10
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentMalignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
1CompletedTreatmentMalignant Neoplasm of Stomach2
1CompletedTreatmentMalignant Pleural Mesothelioma (MPM)1
1CompletedTreatmentMalignant Pleural Mesothelioma (MPM) / Pleural Mesotheliomas1
1CompletedTreatmentMelanoma1
1CompletedTreatmentMesothelioma1
1CompletedTreatmentMesothelioma, Malignant1
1CompletedTreatmentMetastatic Cancers / Tumors, Solid1
1CompletedTreatmentMetastatic Melanoma1
1CompletedTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1CompletedTreatmentNeoplasms4
1CompletedTreatmentNeoplasms, Brain / Neuroblastomas / Sarcomas / Tumors, Central Nervous System1
1CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
1CompletedTreatmentNeoplasms, Head and Neck1
1CompletedTreatmentNeoplasms, Head and Neck / Squamous Cell Carcinoma (SCC)1
1CompletedTreatmentNeoplasms, Malignant2
1CompletedTreatmentNeuroblastomas1
1CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer3
1CompletedTreatmentRecurrent Cervical Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Vaginal Cancer / Recurrent Vulvar Cancer / Stage III Vaginal Cancer / Stage IIIA Cervical Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Vulvar Cancer / Stage IIIB Cervical Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Vulvar Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Vulvar Cancer / Stage IV Ovarian Epithelial Cancer / Stage IVA Cervical Cancer / Stage IVA Vaginal Cancer / Stage IVB Cervical Cancer / Stage IVB Vaginal Cancer1
1CompletedTreatmentSarcomas1
1CompletedTreatmentSolid Cancers1
1CompletedTreatmentSolid Tumors or Mantle Cell Lymphoma1
1CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)3
1CompletedTreatmentStage II Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage II Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Oropharynx1
1CompletedTreatmentStage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
1CompletedTreatmentStage IV Melanoma1
1CompletedTreatmentStomach Neoplasms4
1CompletedTreatmentTriple Negative Breast Cancer (TNBC)1
1CompletedTreatmentTumors, Solid5
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific21
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentNon-Resectable Cholangiocarcinoma / Recurrent Cholangiocarcinoma / Stage III Extrahepatic Bile Duct Cancer / Stage III Intrahepatic Cholangiocarcinoma / Stage IIIA Hilar Cholangiocarcinoma / Stage IIIB Hilar Cholangiocarcinoma / Stage IVA Extrahepatic Bile Duct Cancer / Stage IVA Hilar Cholangiocarcinoma / Stage IVA Intrahepatic Cholangiocarcinoma / Stage IVB Extrahepatic Bile Duct Cancer / Stage IVB Hilar Cholangiocarcinoma / Stage IVB Intrahepatic Cholangiocarcinoma / Unresectable Extrahepatic Bile Duct Carcinoma1
1RecruitingBasic ScienceNeoplasms1
1RecruitingOtherMesothelioma1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Adult Solid Neoplasm / Advanced Malignant Solid Neoplasm / ALK positive / Pancreatic Adenocarcinoma Metastatic / Solid Neoplasms / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1RecruitingTreatmentAbdominal wall neoplasm / Carcinoma, Squamous Cell of Head and Neck / Esophagogastric Junction Neoplasms / Fallopian Tube Neoplasms / Neoplasms, Ovarian / Pancreatic Ductal Carcinoma / Small Cell Lung Carcinoma / Squamous Cell Carcinoma of Esophagus / Stomach Neoplasms / Triple Negative Breast Neoplasms1
1RecruitingTreatmentAdenocarcinoma of Lung Stage IV / Metastatic Malignant Neoplasm in the Brain / Non-Squamous Non-Small Cell Lung Carcinoma / Stage III Large Cell Lung Carcinoma AJCC v7 / Stage III Lung Adenocarcinoma AJCC v7 / Stage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Large Cell Lung Carcinoma / Stage IIIA Large Cell Lung Carcinoma AJCC v7 / Stage IIIA Lung Adenocarcinoma / Stage IIIA Lung Adenocarcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIB Large Cell Lung Carcinoma / Stage IIIB Large Cell Lung Carcinoma AJCC v7 / Stage IIIB Lung Adenocarcinoma / Stage IIIB Lung Adenocarcinoma AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IV Large Cell Lung Carcinoma / Stage IV Large Cell Lung Carcinoma AJCC v7 / Stage IV Lung Adenocarcinoma AJCC v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Head and Neck Squamous Cell Carcinoma (HNSCC) / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma Metastatic / Recurrent Gallbladder Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Gallbladder Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Gallbladder Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Unresectable Gallbladder Carcinoma / Unresectable Pancreatic Cancer1
1RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma1
1RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer / KRAS Gene Mutation / Lung Cancers1
1RecruitingTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentAdvanced Solid Tumors / Malignant Lymphomas / Tumors, Solid1
1RecruitingTreatmentAdvanced Solid Tumors / Tumors, Solid1
1RecruitingTreatmentBiphasic Mesothelioma / Epithelioid Mesothelioma / Stage I Pleural Malignant Mesothelioma AJCC v7 / Stage IA Pleural Malignant Mesothelioma AJCC v7 / Stage IB Pleural Malignant Mesothelioma AJCC v7 / Stage II Pleural Malignant Mesothelioma AJCC v7 / Stage III Pleural Malignant Mesothelioma AJCC v71
1RecruitingTreatmentBladder Cancers1
1RecruitingTreatmentBladder Cancers / Cancer of the Ovary / Cancer of Unknown Primary / Colorectal Cancers / Head and Neck Carcinoma / Sarcomas / Solid Neoplasms / Stage III Pancreatic Cancer / Stage IIIA Breast Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Breast Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IVA Pancreatic Cancer / Stage IVB Pancreatic Cancer1
1RecruitingTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma, Malignant / Metastatic Breast Cancer (MBC) / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentCancer, Breast / Cholangiocarcinomas / Malignant Neoplasm of Colon / Soft Tissue Sarcoma (STS) / Tumors, Solid1
1RecruitingTreatmentCancer, Breast / Neoplasms Metastasis / Neoplasms, Colorectal1
1RecruitingTreatmentCancers / Malignant Neoplasm of Pancreas1
1RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
1RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck / Lung Cancer Non-Small Cell Cancer (NSCLC) / Small Cell Lung Carcinoma1
1RecruitingTreatmentDiseases of Oesophagus Stomach and Duodenum1
1RecruitingTreatmentEndometrioid Adenocarcinoma / Recurrent Cervical Carcinoma / Stage I Uterine Corpus Cancer / Stage I Uterine Corpus Cancer AJCC v7 / Stage I Vaginal Cancer / Stage I Vaginal Cancer AJCC v6 and v7 / Stage IA Uterine Corpus Cancer / Stage IA Uterine Corpus Cancer AJCC v7 / Stage IB Cervical Cancer / Stage IB Cervical Cancer AJCC v6 and v7 / Stage IB Uterine Corpus Cancer / Stage IB Uterine Corpus Cancer AJCC v7 / Stage IB2 Cervical Cancer AJCC v6 and v7 / Stage II Cervical Cancer / Stage II Cervical Cancer AJCC v7 / Stage II Uterine Corpus Cancer / Stage II Uterine Corpus Cancer AJCC v7 / Stage II Vaginal Cancer / Stage II Vaginal Cancer AJCC v6 and v7 / Stage IIA Cervical Cancer / Stage IIA Cervical Cancer AJCC v7 / Stage IIB Cervical Cancer / Stage IIB Cervical Cancer AJCC v6 and v7 / Stage III Cervical Cancer / Stage III Cervical Cancer AJCC v6 and v7 / Stage III Uterine Corpus Cancer / Stage III Uterine Corpus Cancer AJCC v7 / Stage III Vaginal Cancer / Stage III Vaginal Cancer AJCC v6 and v7 / Stage IIIA Cervical Cancer / Stage IIIA Cervical Cancer AJCC v6 and v7 / Stage IIIA Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer AJCC v7 / Stage IIIB Cervical Cancer / Stage IIIB Cervical Cancer AJCC v6 and v7 / Stage IIIB Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer AJCC v7 / Stage IIIC Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer AJCC v71
1RecruitingTreatmentGynecologic Cancers1
1RecruitingTreatmentHead and Neck Carcinoma2
1RecruitingTreatmentHead and Neck Carcinoma / Hypopharynx Cancer / Laryngeal Cancer / Oral Cavity Cancer / Oropharynx Cancers / Squamous Cell Carcinoma (SCC)1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Human Papillomavirus Negative / Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v71
1RecruitingTreatmentHead or Neck Cancer / Metastatic Squamous Cell Carcinoma of the Head and Neck / Recurrent Head and Neck Carcinoma1
1RecruitingTreatmentHypopharynx Squamous Cell Carcinoma / Laryngeal Cancer / Oral Cavity Squamous Cell Carcinoma1
1RecruitingTreatmentLocoregionally Advanced / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms1
1RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1RecruitingTreatmentLung Cancers1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentNeoplasms3
1RecruitingTreatmentNeoplasms, Head and Neck1
1RecruitingTreatmentNon-Small Cell Lung Cancer Recurrent1
1RecruitingTreatmentPleural Effusion, Malignant1
1RecruitingTreatmentPleural Mesotheliomas1
1RecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Cancer / Recurrent Primary Peritoneal Cancer / Recurrent Uterine Corpus Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cavity Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1RecruitingTreatmentStage IIIA Non-Small Cell Lung Cancer1
1RecruitingTreatmentTumors, Solid3
1RecruitingTreatmentUterine Cervix Cancer1
1SuspendedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Stage IB Vulvar Cancer / Stage IB Vulvar Cancer AJCC v7 / Stage IB2 Cervical Cancer / Stage IB2 Cervical Cancer AJCC v6 and v7 / Stage II Vulvar Cancer / Stage II Vulvar Cancer AJCC v7 / Stage IIA1 Cervical Cancer / Stage IIA1 Cervical Cancer AJCC v7 / Stage IIA2 Cervical Cancer / Stage IIA2 Cervical Cancer AJCC v7 / Stage IIB Cervical Cancer / Stage IIB Cervical Cancer AJCC v6 and v7 / Stage IIIA Cervical Cancer / Stage IIIA Cervical Cancer AJCC v6 and v7 / Stage IIIA Vulvar Cancer / Stage IIIA Vulvar Cancer AJCC v7 / Stage IIIB Cervical Cancer / Stage IIIB Cervical Cancer AJCC v6 and v7 / Stage IIIB Vulvar Cancer / Stage IIIB Vulvar Cancer AJCC v7 / Stage IIIC Vulvar Cancer / Stage IIIC Vulvar Cancer AJCC v7 / Stage IVA Cervical Cancer / Stage IVA Cervical Cancer AJCC v6 and v7 / Stage IVA Vulvar Cancer / Stage IVA Vulvar Cancer AJCC v7 / Vulvar Adenocarcinoma / Vulvar Squamous Cell Carcinoma1
1SuspendedTreatmentCDKN2A-p16 Negative / Stage III Hypopharyngeal Squamous Cell Carcinoma / Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage III Laryngeal Squamous Cell Carcinoma / Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7 / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Laryngeal Squamous Cell Carcinoma / Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Oral Cavity Squamous Cell Carcinoma / Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IV Oropharyngeal Squamous Cell Carcinoma / Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Hypopharyngeal Squamous Cell Carcinoma / Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v71
1SuspendedTreatmentCancers1
1SuspendedTreatmentStage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer1
1TerminatedNot AvailableCancers1
1TerminatedOtherCarcinoma, Squamous Cell of Head and Neck1
1TerminatedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1TerminatedTreatmentAdult Solid Neoplasm1
1TerminatedTreatmentAdvanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Metastatic Bladder Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Stage III Pancreatic Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Transitional Cell Carcinoma of the Bladder / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
1TerminatedTreatmentBladder Cancers / Tumors, Solid1
1TerminatedTreatmentCervix Cancer1
1TerminatedTreatmentEsophageal Cancers1
1TerminatedTreatmentEsophageal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas1
1TerminatedTreatmentHead and Neck Carcinoma1
1TerminatedTreatmentInoperable Locally Advanced or Metastatic Biliary Tract Cancer1
1TerminatedTreatmentLung Cancer Metastatic / Sarcoma, Osteogenic1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Tumors, Solid1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
1TerminatedTreatmentMesothelioma1
1TerminatedTreatmentMetastatic Disease1
1TerminatedTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1TerminatedTreatmentNonsmall Cell Lung Cancer Stage III / Nonsquamous Nonsmall Cell Neoplasm of Lung1
1TerminatedTreatmentSalivary Gland Squamous Cell Carcinoma / Stage II Salivary Gland Cancer / Stage II Squamous Cell Carcinoma of the Hypopharynx / Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage II Squamous Cell Carcinoma of the Oropharynx / Stage II Verrucous Carcinoma of the Oral Cavity / Stage III Salivary Gland Cancer / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Verrucous Carcinoma of the Oral Cavity1
1TerminatedTreatmentSquamous Cell Carcinoma (SCC)1
1TerminatedTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Oropharynx1
1TerminatedTreatmentTumors, Solid1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentCervical Carcinoma1
1Unknown StatusTreatmentEsophageal Cancers1
1Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
1Unknown StatusTreatmentLung Cancers2
1Unknown StatusTreatmentMalignant Lymphomas1
1Unknown StatusTreatmentNeoplasms Metastasis / Neoplasms, Lung1
1Unknown StatusTreatmentNon-Small Cell Lung Cancer, Small Cell Lung Cancer / Platinum Responsive Malignancies1
1Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1WithdrawnNot AvailableLocally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)1
1WithdrawnTreatmentAdult Solid Neoplasm / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1WithdrawnTreatmentCervical Cancers3
1WithdrawnTreatmentEpithelial Ovarian Carcinoma / Ovarian Carcinoma, Stage 3 or 4 / Primary Peritoneal Carcinoma1
1WithdrawnTreatmentHead and Neck Carcinoma / Lip and Oral Cavity Cancer / Oropharyngeal Cancers1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Carcinoma (NSCLC) / Tumors, Solid1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer1
1WithdrawnTreatmentLung Cancers2
1WithdrawnTreatmentMalignant Lymphomas1
1WithdrawnTreatmentMalignant Pleural Mesothelioma (MPM)1
1WithdrawnTreatmentMucositis / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
1WithdrawnTreatmentMuscle-invasive Transitional Cell Carcinoma of the Bladder1
1WithdrawnTreatmentRecurrent Ovarian Carcinoma1
1WithdrawnTreatmentSquamous Cell Carcinoma (SCC)1
1, 2Active Not RecruitingTreatmentAdvanced Biliary Tract Carcinoma1
1, 2Active Not RecruitingTreatmentAdvanced Malignant Mesothelioma / Epithelioid Mesothelioma / Pleural Malignant Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatoid Mesothelioma1
1, 2Active Not RecruitingTreatmentAnaplastic Thyroid Cancers / Tumors, Solid1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentCarcinoma of Unknown Primary Origin / Carcinoma, Small Cell / Extensive Stage Small Cell Lung Carcinoma / Large Cell Lung Carcinoma / Neuroendocrine Carcinomas / Newly Diagnosed Carcinoma of Unknown Primary Origin / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
1, 2Active Not RecruitingTreatmentCervical Cancers / Locally Advanced Cervical Cancer1
1, 2Active Not RecruitingTreatmentClassical Hodgkin Lymphoma1
1, 2Active Not RecruitingTreatmentExtensive Stage Small Cell Lung Cancer / Extensive Stage Small Cell Lung Carcinoma / Recurrent Small Cell Lung Carcinoma / Refractory Small cell lung cancer1
1, 2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Human Papillomavirus Infections / Salivary Gland Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oropharyngeal Carcinoma / Stage IVA Oropharyngeal Carcinoma AJCC v7 / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Hypopharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oropharyngeal Carcinoma / Stage IVB Oropharyngeal Carcinoma AJCC v7 / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
1, 2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Pleural Mesothelioma (MPM)1
1, 2Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1, 2Active Not RecruitingTreatmentLung Cancers1
1, 2Active Not RecruitingTreatmentMalignant Tumor of Renal Pelvis / Transitional Cell Carcinoma of Bladder / Ureteral Cancer / Urethral Cancer1
1, 2Active Not RecruitingTreatmentMedulloblastomas1
1, 2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1, 2Active Not RecruitingTreatmentSquamous Non-Small Cell Lung Cancer1
1, 2CompletedSupportive CareHead and Neck Carcinoma / Mucositis1
1, 2CompletedTreatmentAdvanced Carcinoma / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentAdvanced Cervical Cancer1
1, 2CompletedTreatmentAdvanced Gastric Cancer1
1, 2CompletedTreatmentAdvanced Squamous Cell Carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / SSCHN1
1, 2CompletedTreatmentBiliary Tract Cancer1
1, 2CompletedTreatmentBladder Cancers2
1, 2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
1, 2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
1, 2CompletedTreatmentCancer of Head and Neck / Head and Neck Carcinoma / Head Cancer / Neck Cancer / Neoplasms, Neck1
1, 2CompletedTreatmentCancer of the Cervix1
1, 2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1, 2CompletedTreatmentCancer of the Ovary / Testicular germ cell tumour1
1, 2CompletedTreatmentCarcinoma of Head and/or Neck / Squamous Cell Carcinoma (SCC)1
1, 2CompletedTreatmentCarcinoma of Unknown Primary / Head and Neck Carcinoma1
1, 2CompletedTreatmentCarcinoma, Small Cell1
1, 2CompletedTreatmentCervical Cancers2
1, 2CompletedTreatmentCervical Cancers / Radiation Toxicity1
1, 2CompletedTreatmentCholangiocellular Carcinoma2
1, 2CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Radiation Toxicity1
1, 2CompletedTreatmentEsophageal Cancers4
1, 2CompletedTreatmentEsophageal Cancers / Esophagogastric Junction Adenocarcinoma / Malignant Neoplasm of Stomach1
1, 2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer / Lung Cancer Small Cell Lung Cancer (SCLC) / Lung Cancers / Tumors, Solid1
1, 2CompletedTreatmentHead and Neck Carcinoma6
1, 2CompletedTreatmentHepatocellular,Carcinoma1
1, 2CompletedTreatmentHistone Deacetylase Inhibitor / Malignant Neoplasm of Stomach1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
1, 2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1, 2CompletedTreatmentLung Cancers5
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas2
1, 2CompletedTreatmentMalignant Neoplasm of Stomach2
1, 2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)1
1, 2CompletedTreatmentMalignant Pleural Mesothelioma (MPM) / Tumors, Solid1
1, 2CompletedTreatmentMalignant Pleural Mesotherioma1
1, 2CompletedTreatmentMelanoma1
1, 2CompletedTreatmentMetastasis / Neoplasms, Colorectal1
1, 2CompletedTreatmentMetastatic Bladder Cancer / Recurrent Bladder Carcinoma / Stage II Bladder Cancer / Stage III Bladder Cancer1
1, 2CompletedTreatmentMetastatic Melanoma2
1, 2CompletedTreatmentNasopharyngeal Carcinoma1
1, 2CompletedTreatmentNeoplasm, Gastric1
1, 2CompletedTreatmentNeoplasms, Esophageal1
1, 2CompletedTreatmentNeoplasms, Head and Neck1
1, 2CompletedTreatmentOropharynx Cancers / Squamous Cell Carcinoma of the Oral Cavity1
1, 2CompletedTreatmentRecurrent Melanoma / Stage IV Skin Melanoma1
1, 2CompletedTreatmentSquamous Cell Cancer1
1, 2CompletedTreatmentTransitional Cell Carcinoma1
1, 2CompletedTreatmentUrologic Neoplasms1
1, 2CompletedTreatmentUterine Cervical Cancer1
1, 2Not Yet RecruitingTreatmentAdvanced Solid Tumors1
1, 2Not Yet RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1, 2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Not Yet RecruitingTreatmentMelanoma1
1, 2Not Yet RecruitingTreatmentNeuroendocrine Carcinoma of the Skin1
1, 2Not Yet RecruitingTreatmentTransitional Cell Carcinoma1
1, 2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentAdenocarcinoma (PDAC) / Advanced or Metastatic Colorectal Cancer (CRC) / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor / Advanced or Metastatic Solid Tumors / Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Advanced or Metastatic Urothelial Carcinoma (UC) / Colorectal Cancer (CRC) / Head and Neck Carcinoma / Lung Cancers / Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) / Pancreatic Ductal Adenocarcinoma (PDAC) / Tumors, Solid / UC (Urothelial Cancer)1
1, 2RecruitingTreatmentAdenocarcinomas / Digestive System Diseases / Digestive System Neoplasms / Endocrine Gland Neoplasms / Endocrine System Diseases / Neoplasm, Glandular / Neoplasms / Neoplasms Pancreatic / Neoplasms, Pancreatic / Pancreatic Diseases1
1, 2RecruitingTreatmentAdenocarcinomas / Neoplasms, Gastrointestinal1
1, 2RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Advanced Peritoneal Malignant Mesothelioma / Advanced Pleural Malignant Mesothelioma / Advanced thymic carcinoma / Neoplasms, Advanced Solid / Recurrent Malignant Solid Neoplasm / Recurrent Peritoneal Malignant Mesothelioma / Recurrent Pleural Malignant Mesothelioma / Recurrent Solid Neoplasm / Solid Neoplasms / Stage III Non-Small Cell Lung Cancer / Stage III Non-Small Cell Lung Cancer AJCC v7 / Stage III Ovarian Cancer / Stage III Ovarian Cancer AJCC v6 and v7 / Stage III Pleural Malignant Mesothelioma AJCC v7 / Stage III Pleural Mesothelioma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Ovarian Cancer / Stage IIIA Ovarian Cancer AJCC v6 and v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IIIB Ovarian Cancer / Stage IIIB Ovarian Cancer AJCC v6 and v7 / Stage IIIC Ovarian Cancer / Stage IIIC Ovarian Cancer AJCC v6 and v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v7 / Stage IV Ovarian Cancer / Stage IV Ovarian Cancer AJCC v6 and v7 / Stage IV Pleural Malignant Mesothelioma AJCC v7 / Stage IV Pleural Mesothelioma / Unresectable Solid Neoplasm1
1, 2RecruitingTreatmentAdvanced Solid Tumors / Advanced Solid Tumours / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentAdvanced or Metastatic Biliary Tract Cancer (BTC) / Advanced or Metastatic Endometrial Cancer / Advanced or Metastatic Gastroesophageal Cancer (GC) / Advanced or Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) / Advanced or Metastatic Solid Tumors / Recurrent Ovarian Carcinoma1
1, 2RecruitingTreatmentBiliary Tract Cancer1
1, 2RecruitingTreatmentBladder Cancers / Metastatic Bladder Cancer / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentCancer, Breast / Cholangiocarcinomas / Endometrial Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Malignant Neoplasm of Stomach / Malignant Solid Tumours / MPN / MPN (Myeloproliferative Neoplasms) / Multiple Myeloma (MM) / Neoplasms, Endometrial / NSCLC (Non-small Cell Lung Carcinoma) / Solid Tumors and Hematologic Malignancy / Stomach Neoplasms / Transitional Cell Carcinoma / Tumors, Solid / UC (Urothelial Cancer)1
1, 2RecruitingTreatmentCancer, Breast / Triple-Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentCarcinoma, Bronchogenic / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasm, Bronchial / Neoplasms / Neoplasms, Lung / Respiratory Tract Neoplasms / Thoracic Neoplasms1
1, 2RecruitingTreatmentCervical Cancers / Locally Advanced Cervical Cancer1
1, 2RecruitingTreatmentCholangiocarcinomas2
1, 2RecruitingTreatmentHead and Neck Carcinoma2
1, 2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2RecruitingTreatmentMalignant Neoplasm of Breast / Malignant Neoplasms of Bone and Articular Cartilage / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Male Genital Organs / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Respiratory and Intrathoracic Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract / Neoplasms of Uncertain or Unknown Behavior1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas / Pancreas Metastases / Pancreatic Adenocarcinoma Resectable / Pancreatic Ductal Adenocarcinoma1
1, 2RecruitingTreatmentMalignant Neoplasm of Stomach1
1, 2RecruitingTreatmentMesothelioma1
1, 2RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
1, 2RecruitingTreatmentStage IIIA Non-Small Cell Lung Cancer1
1, 2RecruitingTreatmentTo Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy1
1, 2RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1, 2TerminatedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Advanced Gastric Cancer / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Esophageal Cancer / Recurrent Gastric Cancer / Squamous Cell Carcinoma of the Esophagus / Stage III Esophageal Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer / Stage IV Esophageal Cancer1
1, 2TerminatedTreatmentAdvanced or Metastatic Solid Tumors / Previously Untreated Gastric Cancer1
1, 2TerminatedTreatmentAggressive Marginal Zone Lymphoma (MZL) / Burkitt Lymphoma (BL) / Follicular Lymphoma Grade III (FL III°) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL), Blastoid Variant1
1, 2TerminatedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Intestinal Obstruction / Malignant Peritoneal Neoplasm1
1, 2TerminatedTreatmentCarcinoma, Small Cell1
1, 2TerminatedTreatmentCarcinoma, Small Cell / Lung Cancer Small Cell Lung Cancer (SCLC)1
1, 2TerminatedTreatmentCervical Cancers1
1, 2TerminatedTreatmentEstrogen Receptor Negative Breast Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC)1
1, 2TerminatedTreatmentHead and Neck Carcinoma4
1, 2TerminatedTreatmentHead and Neck Carcinoma / Squamous Cell Cancer1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1, 2TerminatedTreatmentMalignant Neoplasm of Stomach1
1, 2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
1, 2TerminatedTreatmentNeoplasms1
1, 2TerminatedTreatmentSmall Cell Lung Carcinoma1
1, 2TerminatedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)2
1, 2Unknown StatusSupportive CareDrug/Agent Toxicity by Tissue/Organ / Head and Neck Carcinoma / Radiation Toxicity1
1, 2Unknown StatusTreatmentAdvanced Gastric Cancer1
1, 2Unknown StatusTreatmentAdvanced Non-Small Cell Lung Cancer1
1, 2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Cancer of the Ovary / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
1, 2Unknown StatusTreatmentCancer, Breast1
1, 2Unknown StatusTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers1
1, 2Unknown StatusTreatmentEsophageal Cancers1
1, 2Unknown StatusTreatmentGastric Carcinoma1
1, 2Unknown StatusTreatmentHead and Neck Carcinoma1
1, 2Unknown StatusTreatmentLocally Advanced Cervical Cancer1
1, 2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Unknown StatusTreatmentNeoplasms, Head and Neck1
1, 2Unknown StatusTreatmentStage IV Pancreatic Cancer1
1, 2Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2WithdrawnTreatmentBladder Cancers1
1, 2WithdrawnTreatmentCancer, Breast1
1, 2WithdrawnTreatmentLung Cancers1
1, 2WithdrawnTreatmentMalignant Pleural Mesothelioma (MPM)1
1, 2WithdrawnTreatmentNeoplasms, Oropharyngeal / Oropharyngeal Cancers / Squamous Carcinoma / Squamous Cell Carcinoma (SCC)1
2Active Not RecruitingDiagnosticSquamous Cell Carcinoma of Oropharynx1
2Active Not RecruitingPreventionPulmonary Relapse of Osteosarcoma1
2Active Not RecruitingTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Stage IB2 Cervical Cancer / Stage II Vaginal Cancer / Stage IIA1 Cervical Cancer / Stage IIA2 Cervical Cancer / Stage IIB Cervical Cancer / Stage III Vaginal Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer / Stage IVA Vaginal Cancer / Vaginal Adenocarcinoma / Vaginal Adenosquamous Carcinoma / Vaginal Squamous Cell Carcinoma1
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Adenosquamous Lung Carcinoma / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Large Cell Lung Carcinoma / Minimally Invasive Lung Adenocarcinoma / Squamous Cell Carcinoma of Lung / Squamous Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentAdrenocortical Carcinoma / Peritoneal Carcinomatosis1
2Active Not RecruitingTreatmentAdvanced Gastric Cancer1
2Active Not RecruitingTreatmentAdvanced Malignant Pleural Mesothelioma1
2Active Not RecruitingTreatmentAnal Basaloid Carcinoma / Anal Canal Cloacogenic Carcinoma / Anal Squamous Cell Carcinoma / Metastatic Anal Canal Carcinoma / Recurrent Anal Canal Carcinoma / Stage IIIB Anal Canal Cancer / Stage IV Anal Canal Cancer1
2Active Not RecruitingTreatmentAnal Canal Carcinoma1
2Active Not RecruitingTreatmentAnal Carcinoma1
2Active Not RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2Active Not RecruitingTreatmentBiliary Tract Cancer2
2Active Not RecruitingTreatmentBiliary Tract Cancer / Cancer, Advanced / Metastatic Cancers1
2Active Not RecruitingTreatmentBladder Cancers3
2Active Not RecruitingTreatmentBladder Cancers / Urachal Cancer / Urethral Cancer1
2Active Not RecruitingTreatmentCancer, Breast3
2Active Not RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck2
2Active Not RecruitingTreatmentChemoradiation / Neoplasms, Esophageal1
2Active Not RecruitingTreatmentCholangiocarcinomas1
2Active Not RecruitingTreatmentDistal Urethral Cancer / Proximal Urethral Cancer / Squamous Cell Carcinoma of the Bladder / Stage II Bladder Cancer / Stage III Bladder Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2Active Not RecruitingTreatmentEsophageal Cancers3
2Active Not RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach2
2Active Not RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentGastrointestinal Cancers1
2Active Not RecruitingTreatmentGerm Cell Tumors1
2Active Not RecruitingTreatmentHead and Neck Carcinoma10
2Active Not RecruitingTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN)2
2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
2Active Not RecruitingTreatmentHepatocellular,Carcinoma / Liver Cancer1
2Active Not RecruitingTreatmentHodgkins Disease (HD)1
2Active Not RecruitingTreatmentHuman Papilloma Virus Infection / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Oropharynx2
2Active Not RecruitingTreatmentLocalized Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter1
2Active Not RecruitingTreatmentLocally Advanced Head and Neck Squamous Cell Carcinoma1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2Active Not RecruitingTreatmentLung Cancers3
2Active Not RecruitingTreatmentMalignant Fibrous Histiocytoma (MFH) of Bone / Sarcoma, Osteogenic1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach4
2Active Not RecruitingTreatmentMesothelioma, Malignant1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingTreatmentNasopharyngeal Carcinoma2
2Active Not RecruitingTreatmentNeoplasms1
2Active Not RecruitingTreatmentNeoplasms by Site / Neoplasms, Head and Neck / Squamous Cell Cancers of the Head and Neck1
2Active Not RecruitingTreatmentNeoplasms, Head and Neck1
2Active Not RecruitingTreatmentNeoplasms, Head and Neck / Neoplasms, Oropharyngeal / Squamous Cell Carcinoma (SCC)2
2Active Not RecruitingTreatmentNon-HPV Locally Advanced Head and Neck Cancer1
2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)2
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Hypopharynx Stage III / Squamous Cell Carcinoma of the Hypopharynx Stage IV / Squamous Cell Carcinoma of the Larynx Stage III / Squamous Cell Carcinoma of the Larynx Stage IV / Squamous Cell Carcinoma of the Oral Cavity Stage III / Squamous Cell Carcinoma of the Oral Cavity Stage IV / Squamous Cell Carcinoma of the Oropharynx Stage III / Squamous Cell Carcinoma of the Oropharynx Stage IV1
2Active Not RecruitingTreatmentStage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
2Active Not RecruitingTreatmentTransitional Cell Carcinoma1
2Active Not RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentUrinary Bladder1
2Approved for MarketingNot AvailableMesothelioma1
2CompletedNot AvailableMesothelioma1
2CompletedNot AvailableTumors, Solid1
2CompletedDiagnosticMalignant Lymphomas1
2CompletedPreventionCancers1
2CompletedPreventionCisplatin Nephrotoxicity1
2CompletedPreventionOral Mucositis / Sarcomas1
2CompletedPreventionUnresectable Locally Advanced NSCLC1
2CompletedSupportive CareBrain and Central Nervous System Tumors1
2CompletedSupportive CareCancer of the Ovary / Cancer, Breast / Drug/Agent Toxicity by Tissue/Organ / Lung Cancers / Malignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedSupportive CareCancers / Chemotherapy-Induced Thrombocytopenia / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Neoplasms, Lung / Oncology / Thrombocytopenias / Tumors, Solid1
2CompletedSupportive CareDrug/Agent Toxicity by Tissue/Organ / Head and Neck Carcinoma / Oral Complications / Radiation Toxicity1
2CompletedSupportive CareMalignant Lymphomas / Neutropenias1
2CompletedTreatmentAbdominal wall neoplasm / Ascites / Yang Deficiency / Yin Deficiency1
2CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Cervical Cancers1
2CompletedTreatmentAdenocarcinoma Of Esophagus1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Adenocarcinoma of GE Junction / Adenocarcinoma of Stomach1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Squamous Cell Carcinoma of Esophagus1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Adenosquamous Cell Carcinoma / Cervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Stage IB Cervical Cancer / Stage IB Cervical Cancer AJCC v6 and v7 / Stage IIA Cervical Cancer / Stage IIA Cervical Cancer AJCC v7 / Stage IIB Cervical Cancer / Stage IIB Cervical Cancer AJCC v6 and v7 / Stage III Cervical Cancer / Stage III Cervical Cancer AJCC v6 and v71
2CompletedTreatmentAdenocarcinoma of the Esophagus / Recurrent Esophageal Cancer / Stage IV Esophageal Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Cancer Recurrent / Squamous Cell Carcinoma of Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Metastatic Brain Tumors1
2CompletedTreatmentAdenocarcinoma of the Stomach / Advanced Gastric Cancer / Malignant Neoplasm of Stomach Stage II / Stage III Gastric Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Gastric Cancer / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Unresectable Gastric Cancer / Metastatic Gastric Cancers1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Malignant Neoplasm of Stomach1
2CompletedTreatmentAdrenocortical Carcinoma1
2CompletedTreatmentAdrenocortical Carcinoma / Brain and Central Nervous System Tumors / Head and Neck Carcinoma / Liver Cancer / Mesothelioma, Malignant / Pheochromocytomas / Sarcomas1
2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
2CompletedTreatmentAdvanced Cancers / Sarcomas1
2CompletedTreatmentAdvanced Gastric Cancer2
2CompletedTreatmentAdvanced Gastric Cancer / Stage III Gastric Cancer1
2CompletedTreatmentAdvanced Malignant Mesothelioma / Epithelial Mesothelioma / Localized Malignant Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
2CompletedTreatmentAdvanced Non-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentAdvanced or Recurrent Esophageal Squamous Cell Carcinoma1
2CompletedTreatmentAnal Carcinoma1
2CompletedTreatmentAnemias / Drug/Agent Toxicity by Tissue/Organ / Lung Cancers / Neutropenias1
2CompletedTreatmentAnxiety Disorders / Depression / Lung Cancers / Tiredness1
2CompletedTreatmentBRCA1 Mutations / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentBiliary Cancer / Malignant Neoplasm of Pancreas1
2CompletedTreatmentBiliary Tract Cancer1
2CompletedTreatmentBiliary Tract Cancer / Gallbladder Cancer1
2CompletedTreatmentBiliary Tract Carcinoma1
2CompletedTreatmentBiliary Tract Carcinoma / Carcinoma of Gallbladder1
2CompletedTreatmentBladder Cancers9
2CompletedTreatmentBladder Cancers / Drug/Agent Toxicity by Tissue/Organ1
2CompletedTreatmentBladder Cancers / Muscle-invasive Bladder Cancer1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentBladder Cancers / Urethral Cancer2
2CompletedTreatmentBladder Cancers / Urinary Bladder1
2CompletedTreatmentBone Metastases / Hormone Refractory Prostate Cancer1
2CompletedTreatmentBrain and Central Nervous System Tumors6
2CompletedTreatmentBrain and Central Nervous System Tumors / Cancer of the Ovary / Extragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
2CompletedTreatmentBrain and Central Nervous System Tumors / Extragonadal Germ Cell Tumor / Pediatric Germ Cell Tumor1
2CompletedTreatmentBrain and Central Nervous System Tumors / Head and Neck Carcinoma / Malignant Lymphomas1
2CompletedTreatmentCancer of Cervix1
2CompletedTreatmentCancer of Head and Neck1
2CompletedTreatmentCancer of Head and Neck / Squamous Cell Cancer1
2CompletedTreatmentCancer of Head / Cancer of Head and Neck / Cancer of Neck / Cancer of the Head / Cancer of the Neck / Cancers of the Head and Neck / Head and Neck Carcinoma / Head Cancer / Head, Neck Neoplasms / Neck Cancer / Neoplasms, Head / Neoplasms, Head and Neck / Neoplasms, Neck / Neoplasms, Upper Aerodigestive Tract / UADT Neoplasms1
2CompletedTreatmentCancer of the Lung / Carcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung1
2CompletedTreatmentCancer of the Ovary3
2CompletedTreatmentCancer of the Ovary / Carcinoid tumour of the gastrointestinal tract / Colorectal Cancers / Gastrointestinal Stromal Tumors / Malignant Neoplasm of Stomach / Peritoneal Cavity Cancer / Small Intestine Cancer1
2CompletedTreatmentCancer of the Ovary / Childhood Germ Cell Tumor / Drug/Agent Toxicity by Tissue/Organ / Extragonadal Germ Cell Tumor1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Metastatic Cancers / Peritoneal Cavity Cancer1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancer of the Ovary / Primary Peritoneal Cavity Cancer2
2CompletedTreatmentCancer of the Pancreatic Head1
2CompletedTreatmentCancer, Breast12
2CompletedTreatmentCancer, Breast / Neoplasms Metastasis1
2CompletedTreatmentCancers1
2CompletedTreatmentCancers / Head and Neck Carcinoma / Oncology / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor1
2CompletedTreatmentCarcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentCarcinoma NOS / Nasopharyngeal Neoplasms1
2CompletedTreatmentCarcinoma of Head/Neck / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentCarcinoma of Larynx / Squamous Cell Carcinoma of the Hypopharynx1
2CompletedTreatmentCarcinoma, Non-Small-Cell Lung (NSCLC)1
2CompletedTreatmentCarcinoma, Non-Small-Cell-Lung Cancer1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentCervical Cancers10
2CompletedTreatmentCervical Cancers / Endometrial Cancers1
2CompletedTreatmentCervical Neoplasms1
2CompletedTreatmentCholangiocarcinomas1
2CompletedTreatmentConcomitant Radiochemotherapy / NSCLC Stage IIIB1
2CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Radiation Toxicity1
2CompletedTreatmentEarly Triple Negative Breast Cancer1
2CompletedTreatmentEffects of Chemotherapy / Malignant Neoplasm of Stomach1
2CompletedTreatmentEfficacy / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Adenosquamous Cell Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Clear Cell Carcinoma / Endometrial Papillary Serous Carcinoma / Endometrial Serous Adenocarcinoma / Stage I Endometrial Carcinoma / Stage IA Uterine Corpus Cancer AJCC v7 / Stage IB Uterine Corpus Cancer AJCC v7 / Stage II Endometrial Carcinoma / Stage II Uterine Corpus Cancer AJCC v7 / Stage III Endometrial Carcinoma / Stage IIIA Uterine Corpus Cancer AJCC v7 / Stage IIIB Uterine Corpus Cancer AJCC v7 / Stage IIIC Uterine Corpus Cancer AJCC v7 / Stage IV Endometrial Carcinoma / Stage IVA Uterine Corpus Cancer AJCC v7 / Stage IVB Uterine Corpus Cancer AJCC v71
2CompletedTreatmentEndometrial Cancers2
2CompletedTreatmentEsophageal Cancers14
2CompletedTreatmentEsophageal Cancers / GE Junction Cancer / Malignant Neoplasm of Stomach1
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach10
2CompletedTreatmentEsophagus Cancer1
2CompletedTreatmentEwing's Sarcoma (ES) / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas1
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer3
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Extensive Stage Small Cell Lung Carcinoma / Recurrent Small Cell Lung Carcinoma / Refractory Small cell lung cancer1
2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
2CompletedTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour2
2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer1
2CompletedTreatmentFallopian Tube Cancer / Primary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
2CompletedTreatmentGastroesophageal Junction Neoplasms / Stomach Neoplasms1
2CompletedTreatmentGastrointestinal Cancers1
2CompletedTreatmentGastrointestinal Cancers / Neuroendocrine Carcinomas1
2CompletedTreatmentGenital Neoplasms, Male1
2CompletedTreatmentGerm Cell Tumors / Testicular Neoplasms1
2CompletedTreatmentHead and Neck1
2CompletedTreatmentHead and Neck Carcinoma25
2CompletedTreatmentHead and Neck Carcinoma / Lung Cancers1
2CompletedTreatmentHead and Neck Carcinoma / Oral Complications of Radiation Therapy / Radiation Toxicity1
2CompletedTreatmentHead and Neck Carcinoma / Precancerous Conditions1
2CompletedTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
2CompletedTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentHigh Risk Urothelial Carcinoma of the Upper Urinary Tracts / Muscle Invasive Bladder Cancer1
2CompletedTreatmentHigh-Grade Gliomas1
2CompletedTreatmentHypopharynx Cancer / Laryngeal Cancer1
2CompletedTreatmentInflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Mucinous Breast Cancer / Tubular Breast Carcinoma1
2CompletedTreatmentLeptomeningeal Metastasis / Metastatic Brain Tumors / Neoplasms, Breast1
2CompletedTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLimited Stage Small Cell Lung Cancer1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLiver Cancer / Metastatic Cancers1
2CompletedTreatmentLocally Advanced Non-Small Cell Lung Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)49
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung2
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)3
2CompletedTreatmentLung Cancers25
2CompletedTreatmentMalignant Ascites / Malignant Pleural Effusions1
2CompletedTreatmentMalignant Lymphomas9
2CompletedTreatmentMalignant Neoplasm of Nasopharynx2
2CompletedTreatmentMalignant Neoplasm of Pancreas15
2CompletedTreatmentMalignant Neoplasm of Stomach19
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)3
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM) / Pleural Mesotheliomas1
2CompletedTreatmentMalignant Solid Tumours1
2CompletedTreatmentMelanoma (Skin)2
2CompletedTreatmentMelanoma / Skin Cancers2
2CompletedTreatmentMesothelioma1
2CompletedTreatmentMesothelioma, Malignant5
2CompletedTreatmentMetastatic Bladder Cancer / Recurrent Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
2CompletedTreatmentMetastatic Bladder Cancer / Urinary Tract Neoplasms / Urologic Neoplasms1
2CompletedTreatmentMetastatic Bone Sarcomas1
2CompletedTreatmentMetastatic Breast Cancer (MBC)5
2CompletedTreatmentMetastatic Cancers / Sarcomas1
2CompletedTreatmentMetastatic Gastric Cancers1
2CompletedTreatmentMetastatic Non-Small Cell Lung Cancer / Nonsquamous Nonsmall Cell Neoplasm of Lung1
2CompletedTreatmentMetastatic Non-squamous Non Small Cell Lung Cancer1
2CompletedTreatmentMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter1
2CompletedTreatmentMetastatic or Recurrent Squamous Cell Carcinoma of Head and Neck1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2CompletedTreatmentNasopharyngeal Carcinoma4
2CompletedTreatmentNasopharyngeal Neoplasms3
2CompletedTreatmentNasopharyngeal Squamous Cell Carcinoma / Toxicity Due to Radiotherapy1
2CompletedTreatmentNeoplasms, Brain / Neuroblastomas / Tumors, Central Nervous System1
2CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Esophageal2
2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2CompletedTreatmentNeoplasms, Gastrointestinal1
2CompletedTreatmentNeoplasms, Head and Neck5
2CompletedTreatmentNeoplasms, Lung3
2CompletedTreatmentNeoplasms, Ovarian2
2CompletedTreatmentNeoplasms, Squamous Cell1
2CompletedTreatmentNeuroblastomas6
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)3
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer4
2CompletedTreatmentOesophageal Carcinoma3
2CompletedTreatmentOvarian Epithelial Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentPancreatic Cancer Metastatic1
2CompletedTreatmentPediatric High Risk Gliomas1
2CompletedTreatmentPenile Cancer2
2CompletedTreatmentPeritoneal Carcinomatosis1
2CompletedTreatmentPleural Neoplasms1
2CompletedTreatmentPrimary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRadiation Induced Mucositis in Head and Neck Cancer1
2CompletedTreatmentRecurrent Cervical Cancer / Recurrent Vaginal Cancer / Stage IB Cervical Cancer / Stage II Vaginal Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage III Vaginal Cancer / Stage IVA Cervical Cancer / Stage IVA Vaginal Cancer / Stage IVB Cervical Cancer / Stage IVB Vaginal Cancer / Therapy-Related Toxicity1
2CompletedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Ovarian Cancer1
2CompletedTreatmentRecurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Primary Peritoneal Cavity Cancer1
2CompletedTreatmentRenal Cancers1
2CompletedTreatmentResected Advanced Gastric Cancer1
2CompletedTreatmentRetinoblastoma1
2CompletedTreatmentSarcoma, Osteogenic1
2CompletedTreatmentSarcomas3
2CompletedTreatmentSquamous Cell Carcinoma (SCC)1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)3
2CompletedTreatmentSquamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)1
2CompletedTreatmentStage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 / Stage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 / Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7 / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 / Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
2CompletedTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
2CompletedTreatmentStage III Vulvar Cancer / Stage IVB Vulvar Cancer / Vulvar Cancers / Vulvar Squamous Cell Carcinoma1
2CompletedTreatmentStage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentStage IV Nasopharyngeal Carcinoma1
2CompletedTreatmentStomach Neoplasms2
2CompletedTreatmentTesticular germ cell tumour1
2CompletedTreatmentTransitional Cell Carcinoma2
2CompletedTreatmentTriple-Negative Breast Cancer (TNBC)1
2CompletedTreatmentUrinary Tract Cancers1
2CompletedTreatmentUrothelial Cancer1
2CompletedTreatmentAdvanced thymic carcinoma1
2Not Yet RecruitingTreatmentAdvanced Head and Neck Cancer1
2Not Yet RecruitingTreatmentBiliary Tract Cancer / Cancer, Advanced / Gallbladder Cancer / Metastatic Cancers1
2Not Yet RecruitingTreatmentBiliary Tract Cancer / Capecitabine / Chemotherapy, Adjuvant / Cholangiocarcinomas / Cisplatin / Gemcitabine1
2Not Yet RecruitingTreatmentBladder Cancers1
2Not Yet RecruitingTreatmentBladder Cancers / Renal Cancers / Transitional Cell Carcinoma / Ureteral Cancer1
2Not Yet RecruitingTreatmentBladder Carcinoma Infiltrating the Muscle of the Bladder Wall / Stage II Bladder Cancer AJCC v8 / Stage II Renal Pelvis Cancer AJCC v8 / Stage II Ureter Cancer AJCC v8 / Stage II Urethral Cancer AJCC v8 / Stage III Bladder Cancer AJCC v8 / Stage III Renal Pelvis Cancer AJCC v8 / Stage III Ureter Cancer AJCC v8 / Stage III Urethral Cancer AJCC v8 / Stage IIIA Bladder Cancer AJCC v8 / Stage IIIB Bladder Cancer AJCC v8 / Urethral Urothelial Carcinoma1
2Not Yet RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2Not Yet RecruitingTreatmentCervical Adenosquamous Cell Carcinoma / Cervical Squamous Cell Carcinoma In Situ / Neoplasms / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer1
2Not Yet RecruitingTreatmentCervical Cancers2
2Not Yet RecruitingTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
2Not Yet RecruitingTreatmentHPV Related Oropharyngeal Squamous Cell Carcinoma1
2Not Yet RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Not Yet RecruitingTreatmentHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Lymphomas1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Not Yet RecruitingTreatmentMalignant Pleural Effusions1
2Not Yet RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Not Yet RecruitingTreatmentNasopharyngeal Carcinoma2
2Not Yet RecruitingTreatmentNasopharyngeal Neoplasms1
2Not Yet RecruitingTreatmentNeoplasm Neck1
2Not Yet RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Not Yet RecruitingTreatmentResectable Cholangiocarcinoma / Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 / Stage II Intrahepatic Cholangiocarcinoma AJCC v8 / Stage III Intrahepatic Cholangiocarcinoma AJCC v8 / Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 / Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v81
2Not Yet RecruitingTreatmentResectable Pancreatic Cancers1
2Not Yet RecruitingTreatmentSquamous Cell Carcinoma Head and Neck1
2Not Yet RecruitingTreatmentStage IIIA Non-Small Cell Lung Cancer1
2Not Yet RecruitingTreatmentTransitional Cell Carcinoma1
2RecruitingNot AvailableSeminoma1
2RecruitingOtherUpper Tract Urothelial Carcinoma1
2RecruitingPreventionMalignant Neoplasm of Stomach1
2RecruitingPreventionMultiple Myeloma (MM)1
2RecruitingPreventionNeoplasms, Head and Neck1
2RecruitingSupportive CareOral Mucositis1
2RecruitingTreatmentAbdominal wall neoplasm / Chemotherapeutic Toxicity / Chemotherapy Effect / Histologic Progression / Metastases to peritoneum / Peritoneum; Carcinomatosis / Quality of Life1
2RecruitingTreatmentAdenocarcinoma Metastatic / Adenocarcinoma of the Biliary Tract / Adenocarinoma Locally Advanced / Biliary Tract Cancer / Extrahepatic Bile Duct Carcinoma / Intrahepatic Cholangiocarcinoma / Non-Resectable Hepatocellular Carcinoma1
2RecruitingTreatmentAdenocarcinoma Of Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Metastatic Esophagogastric Adenocarcinoma / Neoplasm, Gastric / Neoplasms, Esophageal / Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction1
2RecruitingTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Stage IB2 Cervical Cancer / Stage IB2 Cervical Cancer AJCC v6 and v7 / Stage II Cervical Cancer / Stage II Cervical Cancer AJCC v7 / Stage II Vaginal Cancer / Stage II Vaginal Cancer AJCC v6 and v7 / Stage IIA Cervical Cancer / Stage IIA Cervical Cancer AJCC v7 / Stage IIB Cervical Cancer / Stage IIB Cervical Cancer AJCC v6 and v7 / Stage III Vaginal Cancer / Stage III Vaginal Cancer AJCC v6 and v7 / Stage IIIB Cervical Cancer / Stage IIIB Cervical Cancer AJCC v6 and v7 / Stage IVA Cervical Cancer / Stage IVA Cervical Cancer AJCC v6 and v7 / Stage IVA Vaginal Cancer / Stage IVA Vaginal Cancer AJCC v6 and v7 / Stage IVB Vaginal Cancer / Stage IVB Vaginal Cancer AJCC v6 and v7 / Vaginal Adenocarcinoma / Vaginal Adenosquamous Carcinoma / Vaginal Squamous Cell Carcinoma, Not Otherwise Specified1
2RecruitingTreatmentAdenocarcinoma of the Cervix / Stage IB Cervical Cancer / Stage II Cervical Cancer / Stage III Cervical Cancer1
2RecruitingTreatmentAdenocarcinoma of the Lung1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Adenocarcinomas / Malignant Neoplasm of Pancreas / Pancreas Metastases / Pancreatic Ductal Adenocarcinoma1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / BRCA1 Gene Mutation / Brca1 Mutation Carrier / Brca2 Gene Mutation / Brca2 Mutation Carrier / PALB2 Gene Mutation / Pancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v71
2RecruitingTreatmentAdenocarcinomas / Carcinoma, Adenosquamous / Squamous Cell Carcinoma (SCC) / Uterine Cervical Neoplasms1
2RecruitingTreatmentAdenocarcinomas / Neoplasms, Lung1
2RecruitingTreatmentAdrenocortical Carcinoma / Peritoneal Carcinomatosis1
2RecruitingTreatmentAdvanced NSCLC1
2RecruitingTreatmentAdvanced or Recurrent Endometrial Cancer1
2RecruitingTreatmentAnterior Tongue Squamous Cell Carcinoma / Squamous Cell Carcinoma (SCC) / Tongue Neoplasms1
2RecruitingTreatmentAtypical Teratoid Rhabdoid Tumors (ATRT) / Malignant Rhabdoid Tumors (MRT)1
2RecruitingTreatmentBevacizumab / Metastatic Brain Tumors / Non Squamous Non-small Cell Lung Cancer1
2RecruitingTreatmentBiliary Cancer1
2RecruitingTreatmentBiliary Carcinoma / Cholangiocarcinomas / Gall Bladder Carcinoma / Gastrointestinal Tumors1
2RecruitingTreatmentBiliary Tract Cancer1
2RecruitingTreatmentBiliary Tract Neoplasms3
2RecruitingTreatmentBladder Cancers3
2RecruitingTreatmentBrca1 Mutation Carrier / Brca2 Mutation Carrier / Breast Carcinoma Metastatic in the Brain / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v7 / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentCancer of Head and Neck / Cancers of the Head and Neck / Carcinoma, Squamous Cell of the Head and Neck / Head and Neck Carcinoma / Neoplasms, Head and Neck / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingTreatmentCancer of Head and Neck / Carcinoma, Squamous Cell of Head and Neck / Head and Neck Carcinoma / Neoplasms, Head and Neck / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Squamous Cell Carcinoma, Head And Neck1
2RecruitingTreatmentCancer of Unknown Primary Site1
2RecruitingTreatmentCancer of the Ovary1
2RecruitingTreatmentCancer, Breast3
2RecruitingTreatmentCancer, Breast / Metastatic Brain Tumors1
2RecruitingTreatmentCancers of the Head and Neck / Head and Neck Carcinoma / Head and Neck Squamous Cell Carcinoma (HNSCC)1
2RecruitingTreatmentCervical Cancers3
2RecruitingTreatmentChemotherapy, Adjuvant / Histological Type of Neoplasm / Lung Adenocarcinoma, Stage I / Treatments1
2RecruitingTreatmentChildren / Nasopharyngeal Carcinoma1
2RecruitingTreatmentCholangiocarcinoma Non-resectable / Cholangiocarcinomas / Gall Bladder Carcinoma / Gallbladder Carcinoma Non-Resectable1
2RecruitingTreatmentColorectal Large Cell Neuroendocrine Carcinoma / Esophageal Large Cell Neuroendocrine Carcinoma / Gallbladder Large Cell Neuroendocrine Carcinoma / Gastric Large Cell Neuroendocrine Carcinoma / Gastric Neuroendocrine Carcinoma / Intestinal Neuroendocrine Carcinoma / Pancreatic Large Cell Neuroendocrine Carcinoma / Pancreatic Neuroendocrine Carcinoma / Small Intestinal Large Cell Neuroendocrine Carcinoma1
2RecruitingTreatmentConcurrent Chemoradiotherapy / Neoplasms, Esophageal / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentDigestive System Neoplasms / Esophageal Cancers / Neoplasms / Neoplasms, Esophageal1
2RecruitingTreatmentEGFR Mutations / Lung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Brain Tumors1
2RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Recurrent Uterine Corpus Carcinoma1
2RecruitingTreatmentEndometrial Cancers1
2RecruitingTreatmentEpidermal Growth Factor Receptor (EGFR) Protein Overexpression / Malignant Neoplasm of Cardio-esophageal Junction of Stomach / Malignant Neoplasm of Stomach1
2RecruitingTreatmentEsophageal1
2RecruitingTreatmentEsophageal Cancers / Laryngeal Cancer / Lip Cancer / Oral Cancers / Oropharynx Cancers / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2RecruitingTreatmentEsophageal Squamous Cell Carcinoma Resectable1
2RecruitingTreatmentEsophageal, Gastric, or Gastroesophageal Junction Carcinoma1
2RecruitingTreatmentEsophagogastric Junction / Gastric Adenocarcinoma1
2RecruitingTreatmentExtensive Stage Small Cell Lung Carcinoma1
2RecruitingTreatmentFallopian Tube Cancer / Fallopian Tube Carcinoma / Ovarian Carcinoma / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
2RecruitingTreatmentGerm Cell Tumors1
2RecruitingTreatmentHNSCC / HPV-Related Squamous Cell Carcinoma1
2RecruitingTreatmentHPV-Associated Oropharyngeal Squamous Cell Carcinoma / Squamous Cell Carcinoma of the Neck1
2RecruitingTreatmentHead and Neck Carcinoma2
2RecruitingTreatmentHead and Neck Carcinoma / Salivary Gland Tumors1
2RecruitingTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Hypopharyngeal Squamous Cell Carcinoma / Laryngeal Squamous Cell Carcinoma / Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant / Lip and Oral Cavity Squamous Cell Carcinoma / P16INK4a Negative Oropharyngeal Squamous Cell Carcinoma / Stage III Hypopharyngeal Carcinoma AJCC v8 / Stage III Hypopharyngeal Squamous Cell Carcinoma / Stage III Laryngeal Cancer AJCC v8 / Stage III Laryngeal Squamous Cell Carcinoma / Stage III Laryngeal Verrucous Carcinoma / Stage III Lip and Oral Cavity Cancer AJCC v8 / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oral Cavity Verrucous Carcinoma / Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Carcinoma AJCC v8 / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Cancer AJCC v8 / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Lip and Oral Cavity Cancer AJCC v8 / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 / Stage IVA Oropharyngeal Squamous Cell Carcinoma1
2RecruitingTreatmentHepatocellular Carcinoma Non-resectable1
2RecruitingTreatmentHepatocellular,Carcinoma2
2RecruitingTreatmentHer-2 Positive Gastric Cancer / Metastatic Cancers1
2RecruitingTreatmentHypopharyngeal Cancer / Oropharyngeal Cancers1
2RecruitingTreatmentInfiltrating Bladder Urothelial Carcinoma / Stage II Bladder Urothelial Carcinoma / Stage III Bladder Urothelial Carcinoma1
2RecruitingTreatmentLaryngeal Cancer1
2RecruitingTreatmentLocally Advanced Cervical Cancer1
2RecruitingTreatmentLocally Advanced or Metastatic Lung Cancer1
2RecruitingTreatmentLocally Recurrent/Metastatic Triple Negative Breast Cancer1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)8
2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2RecruitingTreatmentLung Cancers1
2RecruitingTreatmentLung Neoplasms, Non-Small Cell Lung Cancer1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMalignant Lymphomas1
2RecruitingTreatmentMalignant Neoplasm of Stomach1
2RecruitingTreatmentMalignant Pleural Effusions1
2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM) / Mesothelioma1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentMedulloblastomas / Untreated Childhood Medulloblastoma1
2RecruitingTreatmentMesothelioma1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentMetastatic Urothelial Carcinoma of the Renal Pelvis and Ureter / Stage IV Bladder Urothelial Carcinoma / Stage IV Bladder Urothelial Carcinoma AJCC v71
2RecruitingTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentMuscle Invasive Bladder Cancer1
2RecruitingTreatmentNasal Cavity Adenocarcinoma / Nasal Cavity Tumor / Paranasal Sinus Cancer1
2RecruitingTreatmentNasopharyngeal Carcinoma5
2RecruitingTreatmentNeuroblastomas1
2RecruitingTreatmentNewly Diagnosed High Risk Neuroblastoma1
2RecruitingTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
2RecruitingTreatmentNon-Squamous Non-Small Cell Lung Carcinoma / Stage I Non-Small Cell Lung Cancer / Stage I Non-Small Cell Lung Cancer AJCC v7 / Stage IA Non-Small Cell Lung Carcinoma / Stage IA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage II Non-Small Cell Lung Cancer / Stage II Non-Small Cell Lung Cancer AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
2RecruitingTreatmentNon-small Cell Lung Cancer Stage IIIA1
2RecruitingTreatmentOropharyngeal Squamous Cell Carcinoma1
2RecruitingTreatmentOvarian Granulosa Cell Tumor / Ovarian Gynandroblastoma / Ovarian Sertoli-Leydig Cell Tumors / Ovarian Sex Cord Tumor With Annular Tubules / Ovarian Sex Cord-Stromal Tumor / Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types / Ovarian Steroid Cell Tumor1
2RecruitingTreatmentParanasal Sinus Neoplasms / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentPatients Diagnosed With Advanced Carcinoma of Uterine Cervix t1
2RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentPoorly differentiated thyroid carcinoma1
2RecruitingTreatmentRecurrent Head and Neck Cancer1
2RecruitingTreatmentSalivary Gland Cancers1
2RecruitingTreatmentSinonasal Tumors1
2RecruitingTreatmentSmall Cell Lung Carcinoma1
2RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus4
2RecruitingTreatmentSquamous Cell Carcinoma of Lung1
2RecruitingTreatmentSquamous Cell Carcinoma of the Anus1
2RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)3
2RecruitingTreatmentSquamous Cell Esophageal Carcinoma1
2RecruitingTreatmentStage II Lymphoepithelioma of the Nasopharynx / Stage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
2RecruitingTreatmentStage III Esophageal Squamous Cell Carcinoma1
2RecruitingTreatmentStage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v71
2RecruitingTreatmentStage IIIA Vulvar Cancer / Stage IIIA Vulvar Cancer AJCC v7 / Stage IIIB Vulvar Cancer / Stage IIIB Vulvar Cancer AJCC v7 / Stage IIIC Vulvar Cancer / Stage IIIC Vulvar Cancer AJCC v7 / Stage IVA Vulvar Cancer / Stage IVA Vulvar Cancer AJCC v7 / Vulvar Squamous Cell Carcinoma1
2RecruitingTreatmentTransitional Cell Carcinoma1
2RecruitingTreatmentTriple-negative Metastatic Breast Cancer1
2RecruitingTreatmentUnresectable Intrahepatic Cholangiocarcinoma1
2RecruitingTreatmentUnresectable Localized Soft Tissue Sarcoma1
2RecruitingTreatmentUnresectable Sinonasal Tumors1
2RecruitingTreatmentUntreated Metastatic Pancreatic Ductal Adenocarcinoma1
2RecruitingTreatmentUrothelial Carcinoma of the Bladder1
2SuspendedTreatmentExtensive Stage Small Cell Lung Carcinoma / Small Cell Lung Carcinoma1
2SuspendedTreatmentLocally Advanced / Transitional Cell Carcinoma / Unresectable1
2SuspendedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2SuspendedTreatmentMetastatic Non-Small Cell Lung Cancer1
2TerminatedDiagnosticMalignant Pleural Mesothelioma (MPM) / Pleural Mesotheliomas1
2TerminatedSupportive CareCancer of the Ovary / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Neurotoxicity / Primary Peritoneal Cavity Cancer / Sarcomas1
2TerminatedSupportive CareChemotherapeutic Agent Toxicity / Mucositis / Radiation Toxicity / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Xerostomia1
2TerminatedSupportive CareNausea and Vomiting / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
2TerminatedTreatmentAdenocarcinoma Of Esophagus / Adenocarcinomas of the Gastroesophageal Junction1
2TerminatedTreatmentAdenocarcinoma of the Esophagus / Esophageal Cancers / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Malignant Neoplasm of Stomach1
2TerminatedTreatmentAdvanced Stage IIIB / High Thymidylate Synthase Expression / Lung Cancer Non-Small Cell Cancer (NSCLC) / Secondary1
2TerminatedTreatmentBile Duct Carcinoma / Cancer of Gallbladder / Cholangiocarcinomas / Hepatobiliary Neoplasms / Liver Cancer1
2TerminatedTreatmentBile Duct Carcinoma / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocellular Carcinoma / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Hepatocellular,Carcinoma / Periampullary Adenocarcinoma1
2TerminatedTreatmentBladder Cancers4
2TerminatedTreatmentCancer of Larynx1
2TerminatedTreatmentCancer of the Ovary1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentCancers / Melanoma1
2TerminatedTreatmentCardiac Toxicity / Sarcomas1
2TerminatedTreatmentCervical Cancers2
2TerminatedTreatmentDrug/Agent Toxicity by Tissue/Organ / Head and Neck Carcinoma / Oral Complications / Radiation Toxicity1
2TerminatedTreatmentEsophageal Cancers5
2TerminatedTreatmentEsophageal Cancers / Gastric Adenocarcinoma / Malignant Neoplasm of Stomach1
2TerminatedTreatmentEsophageal Diseases1
2TerminatedTreatmentFallopian Tube Cancer / Recurrent Ovarian Cancer1
2TerminatedTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Cancer1
2TerminatedTreatmentHead and Neck Carcinoma5
2TerminatedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2TerminatedTreatmentHuman Papilloma Virus (HPV) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2TerminatedTreatmentIntrahepatic Cholangiocarcinoma1
2TerminatedTreatmentLaryngeal Neoplasms / Mouth Neoplasms / Neoplasms, Head and Neck / Neoplasms, Pharyngeal1
2TerminatedTreatmentLocalized Squamous Cell Carcinoma of the Esophagus1
2TerminatedTreatmentLocally Advanced Biliary Tract Cancer / Metastatic Biliary Tract Cancer1
2TerminatedTreatmentLoco-regional Esophageal Cancer1
2TerminatedTreatmentLower Oesophagus Cancer / Oesophageal Junction Cancer / Stomach Neoplasms1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)9
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / NSCLC (Non-small Cell Lung Carcinoma)1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Stage IIIA (N2)1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentLung Cancers7
2TerminatedTreatmentMalignant Neoplasm of Pancreas2
2TerminatedTreatmentMalignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
2TerminatedTreatmentMalignant Neoplasm of Stomach1
2TerminatedTreatmentMedulloblastomas / Neoplasms, Brain / Primitive Neuroectodermal Tumor / Tumors, Central Nervous System1
2TerminatedTreatmentMelanoma1
2TerminatedTreatmentMesothelioma / Pleural Mesotheliomas1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)2
2TerminatedTreatmentMetastatic Non-Small Cell Lung Cancer1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentNeoplasms, Breast1
2TerminatedTreatmentNeoplasms, Oropharyngeal1
2TerminatedTreatmentNeuroblastomas1
2TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer / Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer1
2TerminatedTreatmentOesophageal Carcinoma1
2TerminatedTreatmentOral Cancers / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
2TerminatedTreatmentSarcomas3
2TerminatedTreatmentSmall Cell Lung Carcinoma1
2TerminatedTreatmentStage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
2TerminatedTreatmentTesticular Cancer1
2TerminatedTreatmentAdvanced thymic carcinoma / Thymic Carcinoma1
2TerminatedTreatmentTransitional Cell Carcinoma of the Bladder1
2TerminatedTreatmentUrinary Bladder Neoplasms1
2TerminatedTreatmentUterine Cervical Cancer1
2TerminatedTreatmentUterine Neoplasms1
2Unknown StatusDiagnosticLung Cancers1
2Unknown StatusPreventionAdvanced Gastric Cancer1
2Unknown StatusSupportive CareDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Radiation Toxicity1
2Unknown StatusTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Junction Adenocarcinoma1
2Unknown StatusTreatmentAdvanced Breast Cancer1
2Unknown StatusTreatmentAdvanced Esophageal Squamous Carcinoma1
2Unknown StatusTreatmentAnal Carcinoma1
2Unknown StatusTreatmentBladder Cancers2
2Unknown StatusTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer2
2Unknown StatusTreatmentBrain and Central Nervous System Tumors3
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
2Unknown StatusTreatmentCancer of the Ovary1
2Unknown StatusTreatmentCancer, Breast2
2Unknown StatusTreatmentCervical Cancers5
2Unknown StatusTreatmentDrug Therapy / Genes, EGFR / Neoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC)1
2Unknown StatusTreatmentEsophageal Cancers5
2Unknown StatusTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2Unknown StatusTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
2Unknown StatusTreatmentGerm Cell Tumors1
2Unknown StatusTreatmentHead and Neck Carcinoma7
2Unknown StatusTreatmentHead and Neck Squamous Carcinoma / Nasopharyngeal Carcinoma1
2Unknown StatusTreatmentIntraocular Melanoma1
2Unknown StatusTreatmentLiver Cancer2
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)5
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Stomach / Neuroendocrine Cancer1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2Unknown StatusTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Unknown StatusTreatmentLung Cancers9
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Unknown StatusTreatmentMalignant Gliomas1
2Unknown StatusTreatmentMalignant Lymphomas5
2Unknown StatusTreatmentMalignant Neoplasm of Nasopharynx1
2Unknown StatusTreatmentMalignant Neoplasm of Pancreas2
2Unknown StatusTreatmentMalignant Neoplasm of Stomach3
2Unknown StatusTreatmentMalignant Pleural Mesothelioma (MPM)1
2Unknown StatusTreatmentMalignant / Mesothelioma / Pleural1
2Unknown StatusTreatmentMedulloblastomas / Neoplasms, Brain / Neuroectodermal Tumors, Primitive1
2Unknown StatusTreatmentMelanoma (Skin)1
2Unknown StatusTreatmentMesothelioma, Malignant3
2Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2Unknown StatusTreatmentNasopharyngeal Carcinoma6
2Unknown StatusTreatmentNasophayngeal Carcinoma Between Stage II and IVb1
2Unknown StatusTreatmentNeoplasms, Breast1
2Unknown StatusTreatmentNeoplasms, Head and Neck1
2Unknown StatusTreatmentNeuroblastomas1
2Unknown StatusTreatmentProsthesis Survival1
2Unknown StatusTreatmentRecurrent / Stage IV / Stomach Neoplasms1
2Unknown StatusTreatmentSquamous Cell Carcinoma of Esophagus1
2Unknown StatusTreatmentSquamous Cell Carcinoma of the Head / Squamous Cell Carcinoma of the Neck1
2Unknown StatusTreatmentStage IV Nasopharyngeal Carcinoma1
2Unknown StatusTreatmentStomach Neoplasms2
2WithdrawnDiagnosticStage IIIA Non-Small Cell Lung Cancer1
2WithdrawnTreatmentAdenocarcinomas / Carcinoma NOS / Uterine Cervix Adenosquamous Carcinoma1
2WithdrawnTreatmentAdult Non-Hodgkin's Lymphoma / Anaplastic Large Cell Lymphoma / Lymphoma, AIDS Related1
2WithdrawnTreatmentAdvanced Malignant Mesothelioma / Epithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma1
2WithdrawnTreatmentAnterior Urethral Cancer / Localized Transitional Cell Cancer of the Renal Pelvis and Ureter / Posterior Urethral Cancer / Recurrent Bladder Cancer / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2WithdrawnTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Retinoblastoma / Sarcomas1
2WithdrawnTreatmentCervical Cancers1
2WithdrawnTreatmentCervical Cancers / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer1
2WithdrawnTreatmentHead and Neck Carcinoma3
2WithdrawnTreatmentHepatocellular,Carcinoma1
2WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2WithdrawnTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2WithdrawnTreatmentLung Cancers1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IV Non-Small Cell Lung Cancer1
2WithdrawnTreatmentStage III Non-Small Cell Lung Cancer1
2WithdrawnTreatmentStage III Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Tongue Cancer1
2WithdrawnTreatmentTransitional Cell Carcinoma1
2WithdrawnTreatmentTumors, Solid1
2WithdrawnTreatmentUnknown Primary Tumors1
2, 3Active Not RecruitingTreatmentHead and Neck Carcinoma1
2, 3Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
2, 3Active Not RecruitingTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
2, 3CompletedTreatmentAdenocarcinomas / Esophageal Cancers1
2, 3CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
2, 3CompletedTreatmentBiliary Tract Neoplasms1
2, 3CompletedTreatmentCisplatin Adverse Reaction / Upper GI Cancer1
2, 3CompletedTreatmentEsophageal Cancers2
2, 3CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
2, 3CompletedTreatmentHER-2 Positive Breast Cancer / Inflammatory carcinoma of breast stage IV / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
2, 3CompletedTreatmentHead and Neck Carcinoma1
2, 3CompletedTreatmentLung Cancers1
2, 3CompletedTreatmentMalignant Neoplasm of Pancreas2
2, 3CompletedTreatmentMesothelioma1
2, 3CompletedTreatmentNeoplasm Recurrence, Local / Neoplasms Metastasis / Neoplasms, Head and Neck1
2, 3Enrolling by InvitationTreatmentCancer, Breast1
2, 3Not Yet RecruitingNot AvailableNasopharyngeal Carcinoma1
2, 3Not Yet RecruitingTreatmentCancer, Breast / Chemotherapy Effect / Disease-Free Survival1
2, 3Not Yet RecruitingTreatmentGall Bladder Cancers1
2, 3Not Yet RecruitingTreatmentHuman Papillomavirus (HPV)-Positive Oropharyngeal Cancer1
2, 3RecruitingTreatmentBile Duct Carcinoma / Intrahepatic Cholangiocarcinoma1
2, 3RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2, 3RecruitingTreatmentCancers / Cisplatin Adverse Reaction1
2, 3RecruitingTreatmentCervical Cancers1
2, 3RecruitingTreatmentChildhood Ependymoma1
2, 3RecruitingTreatmentChildhood Hepatocellular Carcinoma / Childhood Malignant Liver Neoplasm / Elevated Alpha-Fetoprotein / Hepatoblastomas / SMARCB1 Gene Mutation1
2, 3RecruitingTreatmentEpstein-Barr Virus Infections / Stage II Nasopharyngeal Carcinoma / Stage III Nasopharyngeal Carcinoma / Stage IVA Nasopharyngeal Carcinoma / Stage IVB Nasopharyngeal Carcinoma1
2, 3RecruitingTreatmentInflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Mucinous Breast Cancer / Tubular Breast Carcinoma1
2, 3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2, 3RecruitingTreatmentMalignant Neoplasm of Esophagus1
2, 3RecruitingTreatmentMalignant Neoplasm of Stomach1
2, 3RecruitingTreatmentMesothelioma1
2, 3RecruitingTreatmentNeoplasms, Brain1
2, 3RecruitingTreatmentOesophagogastric Cancer1
2, 3SuspendedTreatmentSquamous Cell Carcinoma of Esophagus1
2, 3TerminatedTreatmentActivating EGFR Mutation / Lung Cancer Non-Small Cell Cancer (NSCLC) / Non-squamous Non-small Cell Lung Cancer Stage II / Non-squamous Non-small Cell Lung Cancer Stage IIIA / Non-squamous Non-small Cell Lung Cancer Stage IIIB1
2, 3TerminatedTreatmentAnal Carcinoma1
2, 3TerminatedTreatmentEsophageal Cancers1
2, 3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3TerminatedTreatmentMalignant Neoplasm of Stomach / Peritoneal Carcinomatosis1
2, 3Unknown StatusTreatmentEsophageal Cancers1
2, 3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
2, 3Unknown StatusTreatmentHepatocellular,Carcinoma1
2, 3Unknown StatusTreatmentNasopharyngeal Carcinoma1
3Active Not RecruitingNot AvailableBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Children / Ototoxicity1
3Active Not RecruitingPreventionLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Chemotherapeutic Agent Toxicity / Cognitive Side Effects of Cancer Therapy / Psychological Impact of Cancer / Radiation Toxicity / Sexual Dysfunction and Infertility / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer1
3Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
3Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Metastatic Gastric Adenocarcinoma1
3Active Not RecruitingTreatmentBiliary Tract Cancer1
3Active Not RecruitingTreatmentBladder Urothelial Carcinoma / Distal Urethral Carcinoma / Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma / Metastatic Bladder Cancer / Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter / Proximal Urethral Carcinoma / Recurrent Bladder Carcinoma / Recurrent Prostate Carcinoma / Recurrent Urethra Carcinoma / Recurrent Urethral Carcinoma / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter / Stage IV Bladder Cancer AJCC v7 / Stage IV Prostate Cancer / Stage IV Prostate Cancer AJCC v7 / Stage IV Urethral Cancer / Stage IV Urethral Cancer AJCC v7 / Ureter Carcinoma1
3Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
3Active Not RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
3Active Not RecruitingTreatmentCervical Cancers1
3Active Not RecruitingTreatmentCervical Cancers / Uterine Cervical Cancer / Uterine Cervical Neoplasms1
3Active Not RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentEndometrial Cancers1
3Active Not RecruitingTreatmentEndometrial Cancers / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
3Active Not RecruitingTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage IA Uterine Corpus Cancer / Stage IB Uterine Corpus Cancer / Stage II Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer1
3Active Not RecruitingTreatmentEsophageal Cancers1
3Active Not RecruitingTreatmentExtraocular Retinoblastoma1
3Active Not RecruitingTreatmentGastric Adenocarcinoma1
3Active Not RecruitingTreatmentHPV Positive Oropharyngeal Squamous Cell Carcinoma1
3Active Not RecruitingTreatmentHead and Neck Carcinoma4
3Active Not RecruitingTreatmentHead and Neck Carcinoma / Metastatic Head and Neck Squamous Cell Carcinoma / Recurrent Head and Neck Squamous Cell Carcinoma1
3Active Not RecruitingTreatmentHead and Neck Carcinoma / Precancerous Conditions1
3Active Not RecruitingTreatmentHepatocellular,Carcinoma / Non-Resectable Hepatocellular Carcinoma / Unresectable Hepatocellular Carcinoma1
3Active Not RecruitingTreatmentLocalized Osteosarcoma / Metastatic Bone Sarcomas1
3Active Not RecruitingTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Active Not RecruitingTreatmentLocally Advanced Head and Neck HPV Negative Squamous Cell Cancers1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)10
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small-Cell Lung Carcinoma NSCLC1
3Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
3Active Not RecruitingTreatmentMalignant Lymphomas2
3Active Not RecruitingTreatmentMalignant Neoplasm of Nasopharynx1
3Active Not RecruitingTreatmentMalignant Neoplasm of Stomach3
3Active Not RecruitingTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentMesothelioma2
3Active Not RecruitingTreatmentMetastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction1
3Active Not RecruitingTreatmentMetastatic Head and Neck Cancer / Recurrent Head and Neck Cancer1
3Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB2
3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3Active Not RecruitingTreatmentNasopharyngeal Carcinoma3
3Active Not RecruitingTreatmentNasopharyngeal Neoplasms1
3Active Not RecruitingTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
3Active Not RecruitingTreatmentNeoplasms, Oropharyngeal1
3Active Not RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC) / Non Small Cell Lung Carcinoma NSCLC1
3Active Not RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer / Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentPRETEXT Stage 1 Hepatoblastoma / PRETEXT Stage 2 Hepatoblastoma / PRETEXT Stage 3 Hepatoblastoma / PRETEXT Stage 4 Hepatoblastoma1
3Active Not RecruitingTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Major Salivary Gland Cancer AJCC v7 / Stage IV Major Salivary Gland Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Major Salivary Gland Cancer AJCC v7 / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Cancer AJCC v6 and v7 / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Major Salivary Gland Cancer AJCC v7 / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Cancer AJCC v6 and v7 / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVC Major Salivary Gland Cancer AJCC v7 / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVC Oral Cavity Cancer AJCC v6 and v7 / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Tongue Carcinoma / Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary1
3Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)2
3Active Not RecruitingTreatmentStage I Adrenocortical Carcinoma / Stage II Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma1
3Active Not RecruitingTreatmentStage I Lymphoepithelioma of the Nasopharynx / Stage I Squamous Cell Carcinoma of the Nasopharynx / Stage II Lymphoepithelioma of the Nasopharynx / Stage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
3Active Not RecruitingTreatmentStage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
3Active Not RecruitingTreatmentStage IV or Recurrent Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentTransitional Cell Carcinoma1
3Active Not RecruitingTreatmentTransitional Cell Carcinoma of Ureter1
3Active Not RecruitingTreatmentUrothelial Carcinoma Associated 1 RNA, Human1
3CompletedPreventionCancers1
3CompletedSupportive CareAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Anemias / Cervical Squamous Cell Carcinoma / Radiation Toxicity / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer / Therapeutic Agent Toxicity1
3CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IVB Cervical Cancer2
3CompletedTreatmentAdenocarcinoma of the Cervix / Cervical Adenosquamous Cell Carcinoma / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer1
3CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
3CompletedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
3CompletedTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction1
3CompletedTreatmentAdenocarcinomas1
3CompletedTreatmentAdenocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC)2
3CompletedTreatmentAdvanced Gastric Cancer1
3CompletedTreatmentAdvanced Non Small Cell Lung Cancer1
3CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
3CompletedTreatmentAnal Carcinoma2
3CompletedTreatmentAnemias / Head and Neck Carcinoma1
3CompletedTreatmentBladder Cancers1
3CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer2
3CompletedTreatmentBladder Cancers / Urethral Cancer1
3CompletedTreatmentBrain and Central Nervous System Tumors1
3CompletedTreatmentCancer of Cervix1
3CompletedTreatmentCancer of the Larynx / Cancer of the Nasal Cavity / Cancer of the Oral Cavity / Cancer of the Pharynx / Paranasal Sinus Neoplasms1
3CompletedTreatmentCancer of the Ovary2
3CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
3CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
3CompletedTreatmentCancer of the Ovary / Primary Peritoneal Cavity Cancer3
3CompletedTreatmentCancer, Breast2
3CompletedTreatmentCarcinoma, Adrenal Cortical1
3CompletedTreatmentCardiac Toxicity / Sarcomas1
3CompletedTreatmentCervical Cancers6
3CompletedTreatmentChildhood Embryonal Tumor / Childhood Extracranial Germ Cell Tumor / Childhood Extragonadal Germ Cell Tumor / Childhood Malignant Ovarian Germ Cell Tumor / Childhood Malignant Testicular Germ Cell Tumor / Childhood Teratoma / Ovarian Embryonal Carcinoma / Ovarian Yolk Sac Tumor / Stage II Malignant Testicular Germ Cell Tumor / Stage IIA Ovarian Germ Cell Tumor / Stage IIB Ovarian Germ Cell Tumor / Stage IIC Ovarian Germ Cell Tumor / Stage III Malignant Testicular Germ Cell Tumor / Stage IIIA Ovarian Germ Cell Tumor / Stage IIIB Ovarian Germ Cell Tumor / Stage IIIC Ovarian Germ Cell Tumor / Testicular Choriocarcinoma and Yolk Sac Tumor / Testicular Embryonal Carcinoma1
3CompletedTreatmentChildhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
3CompletedTreatmentChildhood Hepatoblastoma / Recurrent Childhood Liver Cancer / Stage I Childhood Liver Cancer1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Malignant Lymphomas / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers1
3CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Testicular germ cell tumour1
3CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer1
3CompletedTreatmentEndometrial Cancers3
3CompletedTreatmentEndometrial Cancers / Psychosocial Effects of Cancer and Its Treatment1
3CompletedTreatmentEsophageal Cancers5
3CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach2
3CompletedTreatmentEsophagus Cancer1
3CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer1
3CompletedTreatmentGeneral Surgery / Malignant Neoplasm of Stomach1
3CompletedTreatmentHead and Neck Carcinoma11
3CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
3CompletedTreatmentInoperable Gastric Cancer1
3CompletedTreatmentLiver Cancer2
3CompletedTreatmentLocally Advanced Bladder Cancer1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)12
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer / Squamous Non-Small Cell Lung Cancer1
3CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)3
3CompletedTreatmentLung Cancers16
3CompletedTreatmentMalignant Lymphomas3
3CompletedTreatmentMalignant Neoplasm of Pancreas2
3CompletedTreatmentMalignant Neoplasm of Stomach13
3CompletedTreatmentMalignant Pleural Effusions1
3CompletedTreatmentMediastinal Cancer / Metastatic Cancers / Testicular germ cell tumour1
3CompletedTreatmentMelanoma (Skin)3
3CompletedTreatmentMelanoma / Skin Cancers1
3CompletedTreatmentMesothelioma, Malignant3
3CompletedTreatmentMetastatic Bladder Cancer / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
3CompletedTreatmentMultiple Myeloma (MM)2
3CompletedTreatmentNasopharyngeal Carcinoma1
3CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
3CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System / Untreated Childhood Medulloblastoma1
3CompletedTreatmentNeoplasms, Head and Neck3
3CompletedTreatmentNeoplasms, Lung1
3CompletedTreatmentNeuroblastomas4
3CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
3CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer2
3CompletedTreatmentOral Cavity / Squamous Cell Carcinoma (SCC)1
3CompletedTreatmentSarcomas2
3CompletedTreatmentSmall Cell Lung Carcinoma2
3CompletedTreatmentSmall Cell Lung Carcinoma, Extensive Disease1
3CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)2
3CompletedTreatmentStomach Neoplasms1
3CompletedTreatmentTransitional Cell Carcinoma of Urinary Bladder1
3CompletedTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor2
3CompletedTreatmentUrinary Bladder Neoplasms1
3Enrolling by InvitationTreatmentBladder Cancers1
3Enrolling by InvitationTreatmentCancer of the Ovary / Neoplasms, Ovarian / Ovarian Germ Cell Cancer1
3Enrolling by InvitationTreatmentCancer of the Ovary / Neoplasms, Ovarian / Ovarian Sex Cord Stromal Tumor1
3Enrolling by InvitationTreatmentEGFR Gene Mutations1
3Enrolling by InvitationTreatmentNasopharyngeal Carcinoma1
3Enrolling by InvitationTreatmentNasopharyngeal Neoplasms1
3Not Yet RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Neoplasm, Gastric1
3Not Yet RecruitingTreatmentCarcinoma Cervix, Stage III1
3Not Yet RecruitingTreatmentCarcinoma of the Cervix, Stage IVB1
3Not Yet RecruitingTreatmentCervical Cancer TNM Staging Regional Lymph Nodes (N)1
3Not Yet RecruitingTreatmentCervical Cancers1
3Not Yet RecruitingTreatmentCervical Carcinoma1
3Not Yet RecruitingTreatmentCompletely Resected NSCLC With Common EGFR Mutations1
3Not Yet RecruitingTreatmentENSAT Stage I Adrenal Cortex Carcinoma / ENSAT Stage II Adrenal Cortex Carcinoma / ENSAT Stage III Adrenal Cortex Carcinoma1
3Not Yet RecruitingTreatmentGestational Trophoblastic Neoplasms1
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Hydrothorax1
3Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3Not Yet RecruitingTreatmentLung Cancers1
3Not Yet RecruitingTreatmentNasopharyngeal Carcinoma3
3Not Yet RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3Not Yet RecruitingTreatmentSquamous Cell Carcinoma of the Penis, Usual Type1
3Not Yet RecruitingTreatmentStage I Gallbladder Cancer AJCC v8 / Stage II Gallbladder Cancer AJCC v8 / Stage IIA Gallbladder Cancer AJCC v8 / Stage IIB Gallbladder Cancer AJCC v8 / Stage III Gallbladder Cancer AJCC v8 / Stage IIIA Gallbladder Cancer AJCC v8 / Stage IIIB Gallbladder Cancer AJCC v81
3RecruitingOtherAdenocarcinoma of Lung Metastatic to Brain / Bevacizumab / Brain Radiotherapy / Cerebral Metastases / Cerebral Radiotherapy / Lung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Non-Small Cell Lung Cancer / Non Epidermoid1
3RecruitingTreatment(FIGO Stage IIB-IVA) / Uterine Cervical Cancer1
3RecruitingTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Stage IA Cervical Cancer / Stage IB Cervical Cancer / Stage IIA Cervical Cancer1
3RecruitingTreatmentAdenocarcinoma of the Oesophago-gastric Junction / Adenocarcinoma of the Oesophagus / Junctional Tumours / Malignant Neoplasm of Esophagus / Oesophageal Tumours1
3RecruitingTreatmentAdult Germ Cell Tumor / Childhood Extracranial Germ Cell Tumor / Childhood Germ Cell Tumor / Extragonadal Embryonal Carcinoma / Grade 2 Immature Ovarian Teratoma / Grade 3 Immature Ovarian Teratoma / Malignant Germ Cell Tumor / Stage I Ovarian Choriocarcinoma / Stage I Ovarian Embryonal Carcinoma / Stage I Ovarian Teratoma / Stage I Ovarian Yolk Sac Tumor / Stage I Testicular Choriocarcinoma / Stage I Testicular Choriocarcinoma AJCC v6 and v7 / Stage I Testicular Embryonal Carcinoma / Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 / Stage I Testicular Yolk Sac Tumor / Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 / Stage II Ovarian Choriocarcinoma / Stage II Ovarian Embryonal Carcinoma / Stage II Ovarian Yolk Sac Tumor / Stage II Testicular Choriocarcinoma / Stage II Testicular Choriocarcinoma AJCC v6 and v7 / Stage II Testicular Embryonal Carcinoma / Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 / Stage II Testicular Yolk Sac Tumor / Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 / Stage III Ovarian Choriocarcinoma / Stage III Ovarian Embryonal Carcinoma / Stage III Ovarian Yolk Sac Tumor / Stage III Testicular Choriocarcinoma / Stage III Testicular Choriocarcinoma AJCC v6 and v7 / Stage III Testicular Embryonal Carcinoma / Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 / Stage III Testicular Yolk Sac Tumor / Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 / Stage IV Ovarian Choriocarcinoma / Stage IV Ovarian Embryonal Carcinoma / Stage IV Ovarian Yolk Sac Tumor / Testicular Mixed Choriocarcinoma and Embryonal Carcinoma / Testicular Mixed Choriocarcinoma and Teratoma / Testicular Mixed Choriocarcinoma and Yolk Sac Tumor1
3RecruitingTreatmentAdvanced Gastric Cancer1
3RecruitingTreatmentBladder Cancers / Urothelial Cancer1
3RecruitingTreatmentBreast Cancer Model / Cancer, Breast / Effects of Chemotherapy1
3RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Epithelial Cancer1
3RecruitingTreatmentCarcinoma,Non-Small-Cell Lung1
3RecruitingTreatmentCarcinoma,Non-Small-Cell Lung / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Carcinomas, Non-Small-Cell1
3RecruitingTreatmentCervical Cancers8
3RecruitingTreatmentCervical Cancers / Chemotherapy, Adjuvant / Lymph Node Metastases / Radiations1
3RecruitingTreatmentCervical Cancers / Lymphocyst / Radiation Therapy1
3RecruitingTreatmentCervical Carcinoma Stage IIB1
3RecruitingTreatmentChemoradiotherapy / Enteral Nutrition Therapy / Squamous Cell Carcinoma of Esophagus1
3RecruitingTreatmentChemotherapeutic Toxicity / Chemotherapy Effect / Stomach Neoplasms1
3RecruitingTreatmentChemotherapy Effects / Esophagus Cancer1
3RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / INRG Stage L2 / INRG Stage M / INRG Stage MS / NMYC Gene Amplification / Recurrent Neuroblastoma1
3RecruitingTreatmentChildhood Infratentorial Ependymoma / Childhood Supratentorial Ependymoma / Newly Diagnosed Childhood Ependymoma1
3RecruitingTreatmentChildhood Teratoma / Choriocarcinoma / Extragonadal Seminoma / Germ Cell Tumors / Germinoma / Malignant Germ Cell Neoplasm / Mixed Germ Cell Tumor / Non-seminomatous Germ Cell Tumors / Seminoma / Teratoma / Yolk Sac Tumor1
3RecruitingTreatmentCholangiocarcinomas / Gall Bladder Carcinoma1
3RecruitingTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer1
3RecruitingTreatmentEsophageal Cancers1
3RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Esophagus / Squamous Cell Carcinoma of Esophagus1
3RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Invasive Breast Carcinoma / Progesterone Receptor Negative / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Carcinoma1
3RecruitingTreatmentFirst Line Non-Small Cell Lung Cancer1
3RecruitingTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
3RecruitingTreatmentGerm Cell Tumors1
3RecruitingTreatmentHNSCC2
3RecruitingTreatmentHead and Neck Carcinoma1
3RecruitingTreatmentHead and Neck Squamous Cell Cancer1
3RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
3RecruitingTreatmentHepatoblastomas / Hepatocellular,Carcinoma1
3RecruitingTreatmentHepatocellular,Carcinoma1
3RecruitingTreatmentHuman Papillomavirus Positive / Oropharyngeal Squamous Cell Carcinoma1
3RecruitingTreatmentInflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Mucinous Breast Cancer / Tubular Breast Carcinoma1
3RecruitingTreatmentInvasive Duct Carcinoma of Breast / Mucinous Breast Cancer / Tubular Breast Carcinoma1
3RecruitingTreatmentLaryngeal Squamous Cell Carcinoma Stage III / Laryngeal Squamous Cell Carcinoma Stage IV / Locally Advanced Malignant Neoplasm / Oropharyngeal Squamous Cell Carcinoma Stage III / Oropharyngeal Squamous Cell Carcinoma Stage IV / Squamous Cell Carcinoma of the Hypopharynx Stage III / Squamous Cell Carcinoma of the Hypopharynx Stage IV / Squamous Cell Carcinoma of the Oral Cavity Stage III / Squamous Cell Carcinoma of the Oral Cavity Stage IV1
3RecruitingTreatmentLocal Advanced Esophageal Squamous Cell Carcinoma / Stage III Esophageal Squamous Cell Carcinoma1
3RecruitingTreatmentLocally Advanced Head and Neck Cancer1
3RecruitingTreatmentLocally Advanced Nasopharyngeal Carcinoma1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)10
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Non-Squamous Non-Small Cell Lung Cancer1
3RecruitingTreatmentLung Cancers1
3RecruitingTreatmentMalignant Neoplasm of Stomach2
3RecruitingTreatmentMultiple Myeloma (MM)1
3RecruitingTreatmentNasopharyngeal Carcinoma8
3RecruitingTreatmentNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type / Non-Hodgkin T-cell Lymphoma / Non-Hodgkin's Lymphoma, Relapsed1
3RecruitingTreatmentNeoplasms, Esophageal3
3RecruitingTreatmentNeoplasms, Head and Neck3
3RecruitingTreatmentNeuroblastomas1
3RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC) / Non Small Cell Lung Carcinoma NSCLC1
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNon-Small-Cell Lung1
3RecruitingTreatmentOligo-metastatic Stage IV Non-small Cell Lung Cancer / Oligo-metastatic Stage IV Non-small Cell Lung Cancer(NSCLC)1
3RecruitingTreatmentOral Mucositis (Ulcerative) Due to Radiation1
3RecruitingTreatmentOropharyngeal Squamous Cell Carcinoma1
3RecruitingTreatmentOropharynx Cancers1
3RecruitingTreatmentProsthesis Survival1
3RecruitingTreatmentSeminoma / Testicular Neoplasms1
3RecruitingTreatmentSmall Cell Lung Carcinoma Extensive Disease1
3RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
3RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3RecruitingTreatmentStage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
3RecruitingTreatmentStage III Intrahepatic Cholangiocarcinoma / Stage IVA Intrahepatic Cholangiocarcinoma1
3RecruitingTreatmentStomach Neoplasms1
3RecruitingTreatmentThymoma and Thymic Carcinoma1
3RecruitingTreatmentUrothelial Cancer1
3RecruitingTreatmentVarious Advanced Cancer1
3SuspendedTreatmentAnaplastic Medulloblastoma / Medulloblastomas / Untreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3SuspendedTreatmentBrain Cancer / Choroid Plexus Tumors1
3TerminatedPreventionHepatocellular,Carcinoma / Liver Cirrhosis / Neoplasm Recurrence, Local / Neoplasms, Hepatic / Recurrences1
3TerminatedSupportive CareHead and Neck Carcinoma / Mucositis / Pain / Radiation Toxicity1
3TerminatedTreatmentBladder Cancers1
3TerminatedTreatmentCancer of the Ovary1
3TerminatedTreatmentCancer, Breast1
3TerminatedTreatmentCervical Cancers3
3TerminatedTreatmentEndometrial Cancers1
3TerminatedTreatmentEsophageal Squamous Cell Cancer1
3TerminatedTreatmentExtensive Disease / First-Line / Lung Cancer Small Cell Lung Cancer (SCLC)1
3TerminatedTreatmentExtragonadal Germ Cell Tumor / Testicular germ cell tumour1
3TerminatedTreatmentHead and Neck Carcinoma3
3TerminatedTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma (SCC)1
3TerminatedTreatmentHilar Cholangiocarcinoma1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
3TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3TerminatedTreatmentLung Cancers4
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentMalignant Neoplasm of Stomach4
3TerminatedTreatmentMultiple Myeloma (MM)1
3TerminatedTreatmentNeoplasms, Esophageal / Squamous Cell Cancer1
3TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
3TerminatedTreatmentSarcomas1
3TerminatedTreatmentVulvar Cancers1
3Unknown StatusScreeningNeoplasms, Lung1
3Unknown StatusTreatmentAnal Carcinoma1
3Unknown StatusTreatmentBladder Cancers2
3Unknown StatusTreatmentBrain and Central Nervous System Tumors3
3Unknown StatusTreatmentCancer of the Ovary1
3Unknown StatusTreatmentCancer of the Ovary / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
3Unknown StatusTreatmentCarcinoma NOS1
3Unknown StatusTreatmentCarcinoma of Unknown Primary1
3Unknown StatusTreatmentCarcinoma, Small Cell1
3Unknown StatusTreatmentCervical Cancers1
3Unknown StatusTreatmentCervix Carcinoma1
3Unknown StatusTreatmentEffects of Chemotherapy / Stage IVC Nasopharyngeal Carcinoma1
3Unknown StatusTreatmentEsophageal Cancers3
3Unknown StatusTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Testicular germ cell tumour1
3Unknown StatusTreatmentHead and Neck Carcinoma3
3Unknown StatusTreatmentLiver Cancer / Ototoxicity1
3Unknown StatusTreatmentLocally Advanced Cervical Cancer1
3Unknown StatusTreatmentLocally Advanced and Metastatic Squamous Cell Carcinoma of the Lung / Lung Cancers / Squamous Cell Carcinoma of the Lung1
3Unknown StatusTreatmentLung Cancers11
3Unknown StatusTreatmentMalignant Lymphomas1
3Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
3Unknown StatusTreatmentMelanoma1
3Unknown StatusTreatmentNasopharyngeal Carcinoma2
3Unknown StatusTreatmentNeuroblastomas3
3Unknown StatusTreatmentNon-squamous Nonsmall Cell Neoplasm of Lung1
3Unknown StatusTreatmentRecurrent, Persistent or Metastasized Cervical Cancer1
3Unknown StatusTreatmentUterine Sarcoma1
3WithdrawnTreatmentCarcinoma NOS / Head and Neck Carcinoma1
3WithdrawnTreatmentCervical Cancers1
3WithdrawnTreatmentEsophageal Cancers1
3WithdrawnTreatmentHead and Neck Carcinoma1
3WithdrawnTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
3WithdrawnTreatmentHepatocellular,Carcinoma1
3WithdrawnTreatmentIntrahepatic Cholangiocarcinoma1
3WithdrawnTreatmentLocalized Resectable Adult Primary Liver Cancer / Stage III Childhood Liver Cancer1
3WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
3WithdrawnTreatmentLung Cancers1
4CompletedNot AvailableEsophageal Cancers1
4CompletedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
4CompletedSupportive CareAnemias / Cervical Cancers1
4CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
4CompletedTreatmentNeoplasms, Head and Neck1
4CompletedTreatmentSquamous Cell Carcinoma (SCC)1
4Not Yet RecruitingTreatmentEsophageal Cancers1
4Not Yet RecruitingTreatmentLung Squamous Cell Carcinoma1
4RecruitingScreeningLiver Injury, Drug-Induced1
4RecruitingTreatmentAdvanced Lung Squamous Carcinoma1
4RecruitingTreatmentIntracranial Germ Cell Tumors1
4RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4RecruitingTreatmentPatients With Head and Neck Cancer (ORL)1
4RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1
4Unknown StatusTreatmentMetastatic Melanoma1
Not AvailableActive Not RecruitingNot AvailableMalnutrition / Nasopharyngeal Carcinoma2
Not AvailableActive Not RecruitingTreatmentBrain and Central Nervous System Tumors1
Not AvailableActive Not RecruitingTreatmentCervical Cancers1
Not AvailableActive Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableActive Not RecruitingTreatmentLung Cancers1
Not AvailableActive Not RecruitingTreatmentMedulloblastomas / Pinealoblastoma / Supratentorial Embryonal Tumor, Not Otherwise Specified / Untreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
Not AvailableActive Not RecruitingTreatmentNasopharyngeal Neoplasms1
Not AvailableActive Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
Not AvailableAvailableNot AvailableMetastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation / Triple-Negative Breast Cancer (TNBC)1
Not AvailableCompletedNot AvailableCervical Intraepithelial Neoplasia (CIN)2
Not AvailableCompletedNot AvailableHead and Neck Carcinoma2
Not AvailableCompletedNot AvailableHead and Neck Squamous Cell Carcinoma (HNSCC)1
Not AvailableCompletedNot AvailableLung Cancer Small Cell Lung Cancer (SCLC)1
Not AvailableCompletedNot AvailableNon-Small Cell Lung Cancer Recurrent / Stage IV Non-Small Cell Lung Cancer1
Not AvailableCompletedNot AvailableSarcoma, Osteogenic / Spindle Cell Sarcoma of Bone1
Not AvailableCompletedDiagnosticEsophageal Cancers / Malignant Neoplasm of Stomach1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors1
Not AvailableCompletedTreatmentCancer, Breast1
Not AvailableCompletedTreatmentChildhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
Not AvailableCompletedTreatmentDisseminated Neuroblastoma / Ganglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableCompletedTreatmentHead and Neck Carcinoma1
Not AvailableCompletedTreatmentHypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
Not AvailableCompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedTreatmentSarcomas1
Not AvailableCompletedTreatmentSquamous Cell Carcinoma of Esophagus1
Not AvailableCompletedTreatmentUterine Cervical Neoplasms1
Not AvailableNot Yet RecruitingTreatmentNasopharyngeal Carcinoma1
Not AvailableNot Yet RecruitingTreatmentOsteosarcoma of Pelvis1
Not AvailableRecruitingNot AvailableCancer of the Ovary / Cancer, Appendiceal / Cervical Cancers / Colorectal Cancers / Fallopian Tube Cancer / Malignant Neoplasm of Stomach / Primary Peritoneal Carcinoma / Uterine Cancers1
Not AvailableRecruitingNot AvailableCancer, Treatment-Related / Cardiovascular Morbidity / Toxicity Due to Chemotherapy1
Not AvailableRecruitingNot AvailableOropharynx Cancers / Squamous Cell Carcinoma (SCC)1
Not AvailableRecruitingTreatmentBladder Cancers / Epirubicin Instillation / Gemcitabine and Cisplatin Chemotherapy / Prognosis / Recurrences1
Not AvailableRecruitingTreatmentCervical Cancers2
Not AvailableRecruitingTreatmentCervical Cancers / Uterine Cancers1
Not AvailableRecruitingTreatmentDrug-Related Side Effects and Adverse Reactions1
Not AvailableRecruitingTreatmentEsophageal Cancers1
Not AvailableRecruitingTreatmentGallbladder Cancer1
Not AvailableRecruitingTreatmentIntrahepatic Cholangiocarcinoma1
Not AvailableRecruitingTreatmentMedulloblastomas1
Not AvailableRecruitingTreatmentNeuroblastomas2
Not AvailableRecruitingTreatmentPleural Effusion, Malignant1
Not AvailableSuspendedTreatmentChemotherapeutic Agent Toxicity / Nephrotoxicity / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableSuspendedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableSuspendedTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Verrucous Carcinoma of the Larynx / Tongue Cancer1
Not AvailableTerminatedPreventionCancers1
Not AvailableTerminatedSupportive CareMalignant Ovarian Mixed Epithelial Tumor / Nausea and Vomiting / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Stage II Ovarian Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Ovarian Carcinoma1
Not AvailableTerminatedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
Not AvailableTerminatedTreatmentFallopian Tube Carcinoma / Ovarian Epithelial Cancer1
Not AvailableTerminatedTreatmentHead and Neck Squamous Cell Cancer1
Not AvailableTerminatedTreatmentNasopharyngeal Neoplasms / Squamous Cell Carcinoma (SCC)1
Not AvailableTerminatedTreatmentResectable Intrahepatic Cholangiocarcinoma / Unresectable Intrahepatic Cholangiocarcinoma1
Not AvailableTerminatedTreatmentSarcoma, Osteogenic1
Not AvailableUnknown StatusNot AvailableHormone Refractory Prostate Cancer1
Not AvailableUnknown StatusNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableUnknown StatusTreatmentChemotherapy, Adjuvant / Hepatocellular,Carcinoma / Survival / Transplantation, Liver / Tumor Recurrence and Metastasis1
Not AvailableUnknown StatusTreatmentEsophageal Cancers1
Not AvailableUnknown StatusTreatmentNasopharyngeal Neoplasms1
Not AvailableUnknown StatusTreatmentNasopharyngeal Neoplasms / Squamous Cell Carcinoma (SCC)1
Not AvailableUnknown StatusTreatmentNeuroblastomas1
Not AvailableWithdrawnSupportive CareNeoplasms, Malignant / Ototoxicity1
Not AvailableWithdrawnTreatmentHead and Neck Carcinoma1
Not AvailableWithdrawnTreatmentHepatocellular,Carcinoma1
Not AvailableWithdrawnTreatmentInfiltrating Bladder Urothelial Carcinoma / Stage II Bladder Urothelial Carcinoma / Stage III Bladder Urothelial Carcinoma / Stage IV Bladder Urothelial Carcinoma1
Not AvailableWithdrawnTreatmentParanasal Sinus Neoplasms1

Pharmacoeconomics

Manufacturers
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Pharmachemie bv
  • Teva parenteral medicines inc
  • Bristol myers co
Packagers
  • APP Pharmaceuticals
  • APPD
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Bristol-Myers Squibb Co.
  • Mead Johnson and Co.
  • Pharmachemie BV
  • Sicor Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
Dosage forms
FormRouteStrength
InjectionIntravenous1 mg/mL
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous100 mg/100mL
Injection, solutionIntravenous50 mg/50mL
LiquidIntravenous.5 mg
LiquidIntravenous1 mg
SolutionIntravenous1.0 mg
SolutionIntravenous1 mg
Injection, powder, lyophilized, for solutionIntravenous1 mg/mL
Prices
Unit descriptionCostUnit
Cisplatin 1 mg/ml vial0.41USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)270 dec °CPhysProp
water solubility2530 mg/L (at 25 °C)AMUNDSEN,AR & STERN,EW (1982)
logP-2.19HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
logP0.041ChemAxon
pKa (Strongest Basic)5.06ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area52.04 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity22.84 m3·mol-1ChemAxon
Polarizability10.31 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9637
Blood Brain Barrier+0.9469
Caco-2 permeable-0.5704
P-glycoprotein substrateNon-substrate0.8714
P-glycoprotein inhibitor INon-inhibitor0.9763
P-glycoprotein inhibitor IINon-inhibitor0.9843
Renal organic cation transporterNon-inhibitor0.9211
CYP450 2C9 substrateNon-substrate0.8069
CYP450 2D6 substrateNon-substrate0.7874
CYP450 3A4 substrateNon-substrate0.7495
CYP450 1A2 substrateNon-inhibitor0.7733
CYP450 2C9 inhibitorNon-inhibitor0.7808
CYP450 2D6 inhibitorNon-inhibitor0.9075
CYP450 2C19 inhibitorNon-inhibitor0.7995
CYP450 3A4 inhibitorNon-inhibitor0.8562
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9204
Ames testNon AMES toxic0.5661
CarcinogenicityCarcinogens 0.5146
BiodegradationNot ready biodegradable0.9213
Rat acute toxicity2.7612 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9774
hERG inhibition (predictor II)Non-inhibitor0.9344
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as transition metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Transition metal salts
Sub Class
Transition metal chlorides
Direct Parent
Transition metal chlorides
Alternative Parents
Inorganic chloride salts
Substituents
Transition metal chloride / Inorganic chloride salt / Inorganic salt
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Yes
Actions
Cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Garcia Sar D, Montes-Bayon M, Aguado Ortiz L, Blanco-Gonzalez E, Sierra LM, Sanz-Medel A: In vivo detection of DNA adducts induced by cisplatin using capillary HPLC-ICP-MS and their correlation with genotoxic damage in Drosophila melanogaster. Anal Bioanal Chem. 2008 Jan;390(1):37-44. Epub 2007 Oct 12. [PubMed:17932658]
  4. Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, Chaney SG: Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol. 2007 Nov 9;373(5):1123-40. Epub 2007 Aug 23. [PubMed:17900616]
  5. Bloemink MJ, Reedijk J: Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Met Ions Biol Syst. 1996;32:641-85. [PubMed:8640534]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Hydrolysis of the deoxyribose N-glycosidic bond to excise 3-methyladenine, and 7-methylguanine from the damaged DNA polymer formed by alkylation lesions.
Specific Function
Alkylbase dna n-glycosylase activity
Gene Name
MPG
Uniprot ID
P29372
Uniprot Name
DNA-3-methyladenine glycosylase
Molecular Weight
32868.365 Da
References
  1. Kartalou M, Samson LD, Essigmann JM: Cisplatin adducts inhibit 1,N(6)-ethenoadenine repair by interacting with the human 3-methyladenine DNA glycosylase. Biochemistry. 2000 Jul 11;39(27):8032-8. [PubMed:10891085]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tumor necrosis factor binding
Specific Function
Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for differen...
Gene Name
A2M
Uniprot ID
P01023
Uniprot Name
Alpha-2-macroglobulin
Molecular Weight
163289.945 Da
References
  1. Khalaila I, Bergamo A, Bussy F, Sava G, Dyson PJ: The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. Int J Oncol. 2006 Jul;29(1):261-8. [PubMed:16773208]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transferrin receptor binding
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
Gene Name
TF
Uniprot ID
P02787
Uniprot Name
Serotransferrin
Molecular Weight
77063.195 Da
References
  1. Khalaila I, Bergamo A, Bussy F, Sava G, Dyson PJ: The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. Int J Oncol. 2006 Jul;29(1):261-8. [PubMed:16773208]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Curator comments
Atox1 protein blocks cisplatin transport to DNA and may lead to drug resistance
General Function
Metallochaperone activity
Specific Function
Binds and deliver cytosolic copper to the copper ATPase proteins. May be important in cellular antioxidant defense.
Gene Name
ATOX1
Uniprot ID
O00244
Uniprot Name
Copper transport protein ATOX1
Molecular Weight
7401.575 Da
References
  1. Xi Z, Guo W, Tian C, Wang F, Liu Y: Copper binding modulates the platination of human copper chaperone Atox1 by antitumor trans-platinum complexes. Metallomics. 2014 Mar;6(3):491-7. doi: 10.1039/c3mt00338h. Epub 2014 Jan 28. [PubMed:24469739]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Erdogan S, Tosyali E, Duzguner V, Kucukgul A, Aslantas O, Celik S: Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26. doi: 10.1016/j.rvsc.2009.09.002. Epub 2009 Oct 8. [PubMed:19818462]
  2. Ozen S, Akyol O, Iraz M, Sogut S, Ozugurlu F, Ozyurt H, Odaci E, Yildirim Z: Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol. 2004 Jan-Feb;24(1):27-35. [PubMed:14745844]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Xanthine oxidase activity
Specific Function
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Ha...
Gene Name
XDH
Uniprot ID
P47989
Uniprot Name
Xanthine dehydrogenase/oxidase
Molecular Weight
146422.99 Da
References
  1. Yilmaz HR, Sogut S, Ozyurt B, Ozugurlu F, Sahin S, Isik B, Uz E, Ozyurt H: The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester. Toxicol Ind Health. 2005 May;21(3-4):67-73. [PubMed:15986578]
  2. Cetin R, Devrim E, Kilicoglu B, Avci A, Candir O, Durak I: Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol. 2006 Jan-Feb;26(1):42-6. [PubMed:16158393]
  3. Erdogan S, Tosyali E, Duzguner V, Kucukgul A, Aslantas O, Celik S: Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26. doi: 10.1016/j.rvsc.2009.09.002. Epub 2009 Oct 8. [PubMed:19818462]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Leukotriene-b4 20-monooxygenase activity
Specific Function
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 2...
Gene Name
CYP4A11
Uniprot ID
Q02928
Uniprot Name
Cytochrome P450 4A11
Molecular Weight
59347.31 Da
References
  1. Nakamura M, Imaoka S, Tanaka E, Misawa S, Funae Y: cis-Diamminedichloroplatinum induces peroxisomes as well as CYP4A1 in rat kidney. Res Commun Mol Pathol Pharmacol. 1998 Jan;99(1):23-32. [PubMed:9523352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Tusgaard B, Norregaard R, Jensen AM, Wang G, Topcu SO, Wang Y, Nielsen S, Frokiaer J: Cisplatin decreases renal cyclooxygenase-2 expression and activity in rats. Acta Physiol (Oxf). 2011 May;202(1):79-90. doi: 10.1111/j.1748-1716.2011.02257.x. Epub 2011 Mar 22. [PubMed:21272267]
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Catalyzes the transfer of the acetyl group from acetyl coenzyme A to the free amino group of arylamines and hydrazines (PubMed:18795795). Is able to utilize not only acetyl-CoA, but also n-propionyl-CoA and acetoacetyl-CoA as acyl donors, although at a lower rate (PubMed:19014350). As acetyl-CoA and propionyl-CoA are products of cholesterol catabolism and the nat gene is likely present in the same operon than genes involved in cholesterol degradation, this enzyme could have a role in the utilization and regulation of these CoA species (PubMed:19014350).
Specific Function
Arylamine n-acetyltransferase activity
Gene Name
nat
Uniprot ID
P9WJI5
Uniprot Name
Arylamine N-acetyltransferase
Molecular Weight
31028.88 Da
References
  1. Ragunathan N, Dairou J, Pluvinage B, Martins M, Petit E, Janel N, Dupret JM, Rodrigues-Lima F: Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition. Mol Pharmacol. 2008 Jun;73(6):1761-8. doi: 10.1124/mol.108.045328. Epub 2008 Feb 29. [PubMed:18310302]
  2. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB: The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004 Oct;66(4):817-23. Epub 2004 Jun 30. [PubMed:15229296]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Masek V, Anzenbacherova E, Machova M, Brabec V, Anzenbacher P: Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs. 2009 Jun;20(5):305-11. [PubMed:19378397]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Masek V, Anzenbacherova E, Machova M, Brabec V, Anzenbacher P: Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs. 2009 Jun;20(5):305-11. [PubMed:19378397]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Bodur E: Human serum butyrylcholinesterase interactions with cisplatin and cyclophosphamide. Biochimie. 2010 Aug;92(8):979-84. doi: 10.1016/j.biochi.2010.04.010. Epub 2010 Apr 24. [PubMed:20417682]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glutathione transferase activity
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Acts on 1,2-epoxy-3-(4-nitrophenoxy)propane, phenethylisothiocyanate 4-nitrobenzyl chlorid...
Gene Name
GSTT1
Uniprot ID
P30711
Uniprot Name
Glutathione S-transferase theta-1
Molecular Weight
27334.755 Da
References
  1. Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, Heinecke A, Horst J, Jurgens H, Lamprecht-Dinnesen A: Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43. [PubMed:11081456]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Zinc ion binding
Specific Function
Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.
Gene Name
MT1A
Uniprot ID
P04731
Uniprot Name
Metallothionein-1A
Molecular Weight
6120.19 Da
References
  1. Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, Zwart N, Dam WA, Sleijfer DT, Mulder NH: Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81. [PubMed:10709094]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Zinc ion binding
Specific Function
Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.
Gene Name
MT2A
Uniprot ID
P02795
Uniprot Name
Metallothionein-2
Molecular Weight
6042.05 Da
References
  1. Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, Zwart N, Dam WA, Sleijfer DT, Mulder NH: Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81. [PubMed:10709094]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Zinc ion binding
Specific Function
Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
Gene Name
SOD1
Uniprot ID
P00441
Uniprot Name
Superoxide dismutase [Cu-Zn]
Molecular Weight
15935.685 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, Heinecke A, Horst J, Jurgens H, Lamprecht-Dinnesen A: Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43. [PubMed:11081456]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Superoxide dismutase activity
Specific Function
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vit...
Gene Name
NQO1
Uniprot ID
P15559
Uniprot Name
NAD(P)H dehydrogenase [quinone] 1
Molecular Weight
30867.405 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name
GSTM1
Uniprot ID
P09488
Uniprot Name
Glutathione S-transferase Mu 1
Molecular Weight
25711.555 Da
References
  1. Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, Heinecke A, Horst J, Jurgens H, Lamprecht-Dinnesen A: Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43. [PubMed:11081456]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Khalaila I, Bergamo A, Bussy F, Sava G, Dyson PJ: The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. Int J Oncol. 2006 Jul;29(1):261-8. [PubMed:16773208]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name
ABCC5
Uniprot ID
O15440
Uniprot Name
Multidrug resistance-associated protein 5
Molecular Weight
160658.8 Da
References
  1. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161]
  2. Demeule M, Brossard M, Beliveau R: Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. Am J Physiol. 1999 Dec;277(6 Pt 2):F832-40. [PubMed:10600929]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Pan BF, Sweet DH, Pritchard JB, Chen R, Nelson JA: A transfected cell model for the renal toxin transporter, rOCT2. Toxicol Sci. 1999 Feb;47(2):181-6. [PubMed:10220855]
  2. Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA: Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 2010 Feb;159(4):898-908. doi: 10.1111/j.1476-5381.2009.00569.x. Epub 2010 Jan 8. [PubMed:20067471]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Copper uptake transmembrane transporter activity
Specific Function
High-affinity, saturable copper transporter involved in dietary copper uptake.
Gene Name
SLC31A1
Uniprot ID
O15431
Uniprot Name
High affinity copper uptake protein 1
Molecular Weight
21090.545 Da
References
  1. Howell SB, Safaei R, Larson CA, Sailor MJ: Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010 Jun;77(6):887-94. doi: 10.1124/mol.109.063172. Epub 2010 Feb 16. [PubMed:20159940]
  2. Kurokawa T, He G, Siddik ZH: Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemother Pharmacol. 2010 Feb;65(3):427-36. doi: 10.1007/s00280-009-1045-2. Epub 2009 Jun 16. [PubMed:19529937]
  3. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB: Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res. 2009 Jan 15;15(2):553-60. doi: 10.1158/1078-0432.CCR-08-2081. [PubMed:19147760]
  4. Liang ZD, Stockton D, Savaraj N, Tien Kuo M: Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol. 2009 Oct;76(4):843-53. doi: 10.1124/mol.109.056416. Epub 2009 Jul 1. [PubMed:19570948]
  5. Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM, Dolan ME: Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):133-42. doi: 10.1007/s00280-008-0860-1. Epub 2008 Nov 8. [PubMed:18998134]
  6. Pabla N, Murphy RF, Liu K, Dong Z: The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009 Mar;296(3):F505-11. doi: 10.1152/ajprenal.90545.2008. Epub 2009 Jan 14. [PubMed:19144690]
  7. Furukawa T, Komatsu M, Ikeda R, Tsujikawa K, Akiyama S: Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem. 2008;15(30):3268-78. [PubMed:19075668]
  8. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB: The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004 Oct;66(4):817-23. Epub 2004 Jun 30. [PubMed:15229296]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Copper ion transmembrane transporter activity
Specific Function
Involved in low-affinity copper uptake.
Gene Name
SLC31A2
Uniprot ID
O15432
Uniprot Name
Probable low affinity copper uptake protein 2
Molecular Weight
15681.29 Da
References
  1. Blair BG, Larson CA, Safaei R, Howell SB: Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res. 2009 Jul 1;15(13):4312-21. doi: 10.1158/1078-0432.CCR-09-0311. Epub 2009 Jun 9. [PubMed:19509135]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4...
Gene Name
ABCC6
Uniprot ID
O95255
Uniprot Name
Multidrug resistance-associated protein 6
Molecular Weight
164904.81 Da
References
  1. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD: Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. [PubMed:12414644]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50. [PubMed:12608535]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Copper-exporting atpase activity
Specific Function
Involved in the export of copper out of the cells, such as the efflux of hepatic copper into the bile.
Gene Name
ATP7B
Uniprot ID
P35670
Uniprot Name
Copper-transporting ATPase 2
Molecular Weight
157261.34 Da
References
  1. Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM, Dolan ME: Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):133-42. doi: 10.1007/s00280-008-0860-1. Epub 2008 Nov 8. [PubMed:18998134]
  2. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26. [PubMed:19470734]
  3. Furukawa T, Komatsu M, Ikeda R, Tsujikawa K, Akiyama S: Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem. 2008;15(30):3268-78. [PubMed:19075668]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Superoxide dismutase copper chaperone activity
Specific Function
May supply copper to copper-requiring proteins within the secretory pathway, when localized in the trans-Golgi network. Under conditions of elevated extracellular copper, it relocalized to the plas...
Gene Name
ATP7A
Uniprot ID
Q04656
Uniprot Name
Copper-transporting ATPase 1
Molecular Weight
163372.275 Da
References
  1. Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM, Dolan ME: Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):133-42. doi: 10.1007/s00280-008-0860-1. Epub 2008 Nov 8. [PubMed:18998134]
  2. Furukawa T, Komatsu M, Ikeda R, Tsujikawa K, Akiyama S: Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem. 2008;15(30):3268-78. [PubMed:19075668]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Ceckova M, Vackova Z, Radilova H, Libra A, Buncek M, Staud F: Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52. doi: 10.1016/j.tiv.2008.09.001. Epub 2008 Sep 9. [PubMed:18801423]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:21